Dissertation zur Erlangung des Doktorgrades
der Fakultät für Chemie und Pharmazie
der Ludwig-Maximilians-Universität München

Biocompatible and precise branched oligomers
for pDNA and siRNA delivery

vorgelegt von

Eveline Edith Salcher (geb. Barth)
aus Temeschburg, Rumänien

2013
Erklärung


Eidesstattliche Versicherung

Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet.

Augsburg, den 10. 03. 2013

.................................................................
(Unterschrift des Autors)

Dissertation eingereicht am: 11. 04. 2013

1. Gutachter: Prof. Dr. Ernst Wagner

2. Gutachter: Prof. Dr. Franz Bracher

Mündliche Prüfung am: 04. 06. 2013
# Table of Contents

## 1 INTRODUCTION

1.1 Therapeutic approach for genetic disorders............................................. 5  
1.2 Bottlenecks within nucleic acid delivery ............................................. 7  
1.3 Overcoming the barriers: Nucleic acid carrier systems ........................... 8  
  1.3.1 Viral vectors............................................................................................ 8  
  1.3.2 Non-viral vectors..................................................................................... 9  
1.4 Towards better defined delivery systems................................................ 13  
1.5 Solid-phase peptide synthesis (SPPS) allows assembly of precise, sequence defined nucleic acid carriers................................................... 14  
1.6 Aims of the thesis...................................................................................... 16

## 2 MATERIALS AND METHODS ..................................................19

2.1 Chemicals and reagents............................................................................ 19  
2.2 General methods for SPPS-based oligomer synthesis ......................... 20  
  2.2.1 Syntheses of cationic building blocks.................................................... 20  
  2.2.2 General methods for oligomers synthesis by manual SPPS................. 20  
  2.2.3 DMF test on amine impurities ............................................................... 20  
  2.2.4 Fmoc quantification............................................................................... 21  
  2.2.5 Kaiser Test............................................................................................ 21  
  2.2.6 Introduction of Triton X-100................................................................... 21  
2.3 Syntheses of four- and five-arm oligomers ............................................. 22  
  2.3.1 Synthesis of four-arm core.................................................................... 22  
  2.3.2 Synthesis of four-arm Stp oligomers.................................................... 22  
  2.3.3 Synthesis of terminally modified four-arm Stp, Gtt and Sph oligomers . 23  
  2.3.4 Synthesis of five-arm Stp oligomers..................................................... 23  
  2.3.5 Synthesis of histidine-containing four-arm oligomers....................... 24  
  2.3.6 Synthesis of linear Stp oligomers......................................................... 24  
  2.3.7 Synthesis of Boc-Cys(NPys)-pentafluorophenyl ester (BCNP-OPfp) .. 25  
  2.3.8 Synthesis of activated PPI core (PPI-CNP)........................................ 25  
  2.3.9 Assembly of PPI conjugates................................................................. 26  
2.4 Methods and devices for compound purification and chemical characterization .................................................................................................................... 26  
  2.4.1 Dialysis .................................................................................................. 26
2.4.2 Size exclusion chromatography ............................................................ 26
2.4.3 Analytical ion exchange chromatography (IEX-HPLC) ...................... 26
2.4.4 Analytical reversed phase HPLC (RP-HPLC) .................................... 26
2.4.5 $^1$H-NMR ................................................................................................. 27
2.4.6 Mass Spectrometry ............................................................................... 27
2.4.7 3-Nitro-2-pyridinesulfenyl (NPys) quantification ............................... 27
2.4.8 Quantification of 3-Nitro-pyridine-2-thione (NPythione) ................. 27
2.4.9 Ellman’s assay [158] ............................................................................. 27
2.4.10 Tris(2-carboxyethyl)phosphine (TCEP) assay ................................. 28

2.5 Biophysical and biological characterization ........................................... 28
2.5.1 Acidimetric titrations of histidine containing oligomers .................. 28
2.5.2 Polyplex formation ................................................................................ 28
2.5.3 Measurement of particle size and zeta potential ............................... 29
2.5.4 pDNA binding assay ............................................................................. 29
2.5.5 siRNA binding assay ............................................................................. 29
2.5.6 pDNA polyplex dissociation assay ........................................................ 29
2.5.7 Ethidium bromide exclusion assay ........................................................ 29

2.6 Cell culture ................................................................................................. 30
2.6.1 Luciferase reporter gene expression ..................................................... 30
2.6.2 Cell viability assay (MTT assay) ............................................................ 30
2.6.3 Luciferase gene silencing ...................................................................... 31

3 RESULTS ........................................................................................................32
3.1 Four- and five-arm oligo(ethanamino)amides for pDNA and siRNA delivery ........................................................................................................ 32
3.1.1 Introduction ........................................................................................... 32
3.1.2 General synthesis and library design .................................................... 34
3.1.3 Four-arm Stp oligomers for pDNA delivery ........................................ 36
3.1.4 Effect of introduction of cysteines ....................................................... 38
3.1.5 Effect of Stp replacement by shorter building block Gtt ................... 41
3.1.6 Effect of Stp replacement by longer building block Sph .................... 42
3.1.7 Four-arm cysteine containing Stp, Gtt and Sph oligomers for siRNA delivery ........................................................................................................ 44
3.1.8 Five-arm Stp oligomers for pDNA and siRNA delivery ..................... 47

3.2 Histidine-containing Stp and Gtt oligomers .......................................... 49
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.7.2</td>
<td>Book chapters</td>
<td>89</td>
</tr>
<tr>
<td>7.7.3</td>
<td>Poster presentation</td>
<td>90</td>
</tr>
<tr>
<td>7.7.4</td>
<td>Oral presentation</td>
<td>90</td>
</tr>
<tr>
<td>8</td>
<td>REFERENCES</td>
<td>91</td>
</tr>
<tr>
<td>9</td>
<td>ACKNOWLEDGEMENTS</td>
<td>107</td>
</tr>
</tbody>
</table>
1 INTRODUCTION

1.1 Therapeutic approach for genetic disorders

Many severe diseases like congenital disorders and various cancer forms can be traced back to inaccurate processes on cellular level and are still beyond remedy. Therefore, many scientists have dedicated themselves to the quest for finding a cure for such disorders. By replacing or interfering with missing and defective genes they tackle the problem at its origin.

Meanwhile, there are several possibilities of approaching this topic. Therapeutic DNA, for instance, can be delivered to the nucleus of the target cells so as to replace missing or defective genes (Fig. 1). More than thirty years ago, T. Friedmann and R. Roblin discussed the at that time controversial issue of treating genetically determined disorders with therapeutic DNA [1]. During the last decades vast progress has been made in this field and although gene therapy is not an established treatment form yet, there are several clinical trials ongoing [2-5]. The spectrum of the treated disorders is broad, trying to cure inherited monogenic diseases (e.g. Severe combined immunodeficiency (SCID), Leber’s congenital amaurosis (LCA), Hemophilia B), infectious diseases (e.g. HIV, Hepatitis C) or cardiovascular disorders, to mention but a few examples. Nevertheless, the majority of clinical trials address various cancer forms, among others gastrointestinal and prostate tumors or cancer of the nervous system, as they occur with a very high prevalence and often are fatal.

Another approach which got in the last twenty years more and more into focus is the use of oligonucleotides aiming for specific targets within the cell. Oligonucleotides are short fragments of nucleic acids which can fulfill, depending on their nature, various tasks, thereby following one aim: regulation of inaccurate processes within the cell. Different classes have been evaluated for their therapeutic potential, either taking advantage of the antisense technology [6-9], or making use of other short nucleic acids such as decoy oligodeoxynucleotides [10], aptamers [11], polyinosine-cytosine RNA (polyIC) [12, 13] or antagonirs [14, 15].

However, the perhaps best-known oligonucleotide and its applications is small interfering RNA (siRNA). Meanwhile, it is more or less general knowledge that Andrew Fire and Craig Mello, received the Nobel Prize in 2006 for their work on RNA
interference (RNAi) in 1998. They described the impact of exogenous double-stranded RNA (dsRNA) on specific silencing of genes compared to delivered single strands in the nematode *Caenorhabditis elegans* [16]. Almost equally famous is the work of T. Tuschl and colleagues on the application of exogenous synthetic 21-nucleotide dsRNAs (also: small interfering RNAs; siRNAs) and their capability for gene silencing in mammalian cells three years later [17]. The pathway of RNA interference (RNAi) with double-stranded siRNA starts in the cytosol with its incorporation into the RNA-induced silencing complex (RISC). In the so-called Pre-RISC complex the `passenger` strand is degraded by an Argonaute (AGO) protein. The thus activated RISC contains AGO and the `guide` strand, which can then associate with the complementary target messenger RNA (mRNA). Subsequent mRNA cleavage leads to suppression of transcription of the corresponding gene (Fig. 1). Therefore, RNA interference leads to highly sequence-specific and efficient posttranscriptional gene silencing of target genes. Since the discovery that this pathway can be harnessed for therapeutic purposes, application in humans has rapidly advanced towards clinical trials [18, 19].

![Fig. 1. pDNA and siRNA pathway within the cell.](image)

pDNA, after entering the cell, is imported into the nucleus, where it leads to gene expression. SiRNA, for its part, is incorporated into the Pre-RISC complex, where the `passenger` strand is cleaved. The `guide` strand within the activated RISC binds to the target mRNA which is subsequently cleaved by the Argonaute (AGO) protein, thus leading to gene silencing.


1.2 Bottlenecks within nucleic acid delivery

Although research in the field of nucleic acid delivery is already far advanced, there is still need for the optimal delivery system, as the payload encounters several obstacles on the way to its site of action. Therefore, nucleic acid delivery to the target cell compartment is not an easy task, but as the drawbacks are known, they can be targeted for optimization.

When aiming at systemic administration of the pure therapeutic nucleic acid, reaching the target cells within the body undamaged is the major challenge after application. Enzymatic degradation during blood circulation by nucleases [20] and rapid renal clearance [21] are the first drawbacks which must be overcome. When applied locally, passing the anionic barrier cell membrane is an almost insuperable task due to electrostatic repulsion of the negatively charged nucleic acid phosphate backbone. Furthermore, as the size of both pDNA and siRNA is relatively large, internalization by passive diffusion is hampered. Additionally, in contrast to siRNA which acts in the cytosol, pDNA has to reach and enter the nucleus in order to allow transcription and thus mediate gene expression. A major obstacle within the cell is the transport to the nucleus, as the cellular actin cytoskeleton impedes migration of the pDNA towards its site of action [22, 23]. Active nuclear import through the nuclear pore complex (NPC) is hampered in non-dividing cells for particles larger than approximately 10 nm [24-26]; proliferating cells allow passive nuclear import during cell division [27, 28]. Therefore, the nucleic acid needs an efficient carrier with the ability to condense it to an appropriate small particle size, to protect it during blood circulation without inducing unspecific interactions with blood components and to mediate cellular uptake in target cells without damaging the cell membrane.

After internalization, the carrier has not completed its task; it has to help the payload escape endosomal entrapment. The particles are mostly found in intracellular vesicles after cellular uptake, which fuse to early endosomes. The pH within these early endosomes drops to 5.9 – 6, whereas maturation takes place by further acidification due to ATP-driven proton pumps in the endosomal membrane. As the the composition of the intra-endosomal environment cannot facilitate digestion of all proteins and lipids, late endosomes undergo fusion with lysosomes. Lysosomes contain additional enzymes, including nucleases, which would lead to nucleic acid degradation, unless the carrier facilitates endosomal escape before reaching this state. Finally, after release into the cytosol, the carrier has to set free its undamaged
cargo in or near the desired target cell compartment, namely the nucleus for DNA and the cytosol for siRNA. Concerning pDNA, late endosomal escape after microtubular transport of the vesicles to the perinuclear region is of advantage [29, 30], in order to avoid hampered cargo transport within the cell. **Fig. 2** shows exemplarily the pathway of a polyplex assembled with a cationic polymer containing a degradable disulfide linkage and the negatively charged nucleic acid.

![Fig. 2. Nucleic acid delivery](image_url)

**Fig. 2. Nucleic acid delivery** exemplified by using a cationic polymer containing degradable disulfide linkages as carrier system. Polyplex formation takes place due to electrostatic interactions. After cellular uptake of the polyplex by endocytosis and endosomal escape, siRNA is further processed in the cytosol whereas pDNA has to enter the nucleus.

### 1.3 Overcoming the barriers: Nucleic acid carrier systems

#### 1.3.1 Viral vectors

In search of efficient and biocompatible gene therapy, manifold carrier systems have been developed and investigated. However, the ideal carrier was already invented by nature – the virus. Due to its natural programming of inserting viral genetic material into target cells, it is capable of adapting to differing environmental conditions between extra- and intracellular compartments like enzymes, pH or redox potential. And indeed, this is the secret of its high efficiency, as it can dynamically change its conformation on environmental demand, securely leading the genetic material to its biological site of action [31].

Different viral vector systems have been evaluated during the last decade for gene and oligonucleotide delivery, whereas adenoviruses [32], adeno-associated viruses
(AAV) [33] and lentiviruses (LV) [34], a subclass of retroviruses, were the most commonly vectors used for gene therapy.

Gene silencing by taking advantage of the RNAi pathway could be achieved also by means of viral vectors [35]. Delivery of siRNA itself has only a transient effect, though, as siRNA acts in the cytosol and the amount decreases rapidly during cell division. Hence, another strategy was explored, namely the sustained intracellular expression of siRNA from plasmid DNA as shRNA, as shown by Brummelkamp et al. [9] and Paddison and colleagues [36]. Insertion of cassettes encoding for the corresponding shRNA, which are transcribed in the nucleus and further processed in the cytosol led to prolonged siRNA expression.

Nevertheless, there are good reasons why viral gene therapy is still handled with caution – the risk for serious host immune response [37], occurrence of mutagenic integration [38], limited loading capacity and high production costs still limit clinical application [39].

1.3.2 Non-viral vectors

In the field of non-viral gene delivery systems, cationic polymers and cationic lipids have meanwhile received much attention [40, 41] as they are able to circumvent some of the disadvantages associated with viral vectors, e.g. by displaying higher biocompatibility as they do not provoke such high immune response [42], higher loading capacity and feasibility for large-scale production. Unfortunately, they still cannot achieve comparable transfection efficiency. Hence, as such carriers offer manifold possibilities for optimization, much effort has been put into increasing the therapeutic potential.

A cationic lipid formulation entrapping DNA for in vitro transfection was first reported by Felgner et al. in 1987 [43]. Due to ionic interactions between the positively charged lipid head group and the negatively charged DNA, so called “lipoplexes” were formed. Since then, cationic lipid formulations for nucleic acid delivery have been further developed, even entering clinical trials [44-46].

In 1962, Smull and Ludwig observed an infection enhancement of eukaryotic tumor cells when RNA was mixed with the cationic proteins histone and protamine before adding it to cell culture medium [47]. Such complexes formed due to electrostatic interactions between a cationic compound and the negatively charged nucleic acid were later termed “polyplexes” [48]. The advantage of such interplay between carrier and cargo is that the interaction takes place in a non-damaging reversible manner. A
further benefit of cationic polymers is that these can be chemically designed and
produced which leaves room for further specific modifications directed to creating
non-immunogenic, bioresponsive and dynamically acting molecules.
Non-adaptable, synthetic cationic polymer-based systems, such as branched and
linear poly(ethylenimine); PEI, poly(lysine); PLL, dendritic poly(amido amine); PAMAM
and poly(propylenimine); PPI were already widely evaluated as nucleic acid
delivery systems. The correlation between transfection efficiency and cytotoxicity has
been shown to be unsatisfactory though, i.e. effective transfection agents like PEI
displayed also undesired cytotoxic effects [49, 50].
Although within the polyplex the nucleic acid should be protected during blood
circulation, unspecific interactions with blood components and therefore rapid
clearance from the blood stream [51, 52], unspecific interactions with non-target cells,
formation of aggregates at physiological salt concentrations [53] and resultant
cytotoxic effects still can occur. Chemical incorporation of hydrophilic moieties like
the widely used PEG for electrostatic shielding offers a way to overcome these
problems. PEGylation shows not only an elongated blood circulation time, but also
better water solubility and reduced cytotoxicity [54]. Transfection efficiency, however,
is also reduced [55, 56] due to limited interaction of the shielded positive polymer
charges with the negatively charged cell membrane. Besides that, PEG shielding
hampers intracellular release of DNA and siRNA from endosomal vesicles [57, 58].
Including targeting ligands in PEGylated polyplexes is one way to enhance
transfection efficiency as cellular uptake is improved due to receptor-mediated
endocytosis [59-61]. An additional possibility is to increase the cytosolic release of
DNA or siRNA by chemically programmed PEG-polymer linkages to be pH-sensitive
and thus cleavable in the endosome [62-64].
Reaching the target tissue after systemic delivery faces an enormous challenge: the
vascular barrier. Extravasation barriers differ from tissue to tissue. While CNS is
extremely well protected against extravasating agents by the blood brain barrier,
hepatocytes, inflammation sites or tumor sites are much more accessible. In the latter
case the tumor tissue can be achieved either by “passive” or “active” targeting.
Passive targeting takes advantage of the enhanced permeability and retention (EPR)
effect [65]. This phenomenon implies polymer accumulation in tumor tissue due to its
leaky vasculature and deficient lymphatic clearance [66].
Active targeting implies the conjugation of targeting ligands to nucleic acid carrier systems which specifically bind to receptors expressed on cell surfaces, as tumor cells often show an over-expression of a series of specific receptors. First shown for DNA delivery by conjugation of hepatocyte target moiety asialoorosomucoid (ASOR) to polylysine over twenty years ago [67], there are various ligands which can be used for active targeting, such as transferrin [68], epidermal growth factor (EGF) [30], RGD [69, 70] or folic acid [71, 72].

Once internalized, the essential step for the polyplex is to rapidly escape the endosomal vesicle in order to release the nucleic acid in the cytosol and prevent its lysosomal degradation. As the endosomal and lysosomal pH presents values between 4.5 and 6.5 and therefore differs from the neutral pH of 7.4 in other biological compartments [73], this characteristic can be taken advantage of by using different strategies.

Within the class of cationic polymers, polyethylenimine (PEI) has unique favorable properties for intracellular nucleic acid delivery. Synthetic variations in both molecular weight and structure are possible, also with differing effect on efficiency and biocompatibility [74, 75]. PEI has outstanding properties concerning pDNA binding ability and buffering capacity for endosomal escape due to the 1,2-diaminoethane motif [76-78]. Due to its high charge density [74] it facilitates endosomal escape by taking advantage of the so-called “proton sponge effect” [79]. PEI nitrogens are only moderately protonated at physiological pH [80], whereas protonation increases upon endosomal acidification. Due to proton accumulation within the vesicle and therefore high density of positive charge, the influx of chloride and water is increased. Finally, the osmotic pressure and membrane destabilization effect of the cationic compound leads to endosome disruption and thus to particle release into the cytosol. Current investigation on the impact of the length of such moieties containing the diaminoethane motif revealed the correlation between amount of protonable amines, position within the chain and buffering capacity [81-83].

The imidazole group within the histidine side chain can be also used as a buffering domain. Due to its chemical structure protonation occurs only at an acidic pH value, which makes this amino acid interesting for enhancing endosomal escape by the proton sponge effect. Therefore, it was often chemically integrated in nucleic acid carriers and various research groups could show enhanced transfection efficacy due to histidine introduction. Midoux and Monsigny showed first enhanced pDNA
transfection of the cationic polymer polylysine modified with histidine residues in 1999 [84]. Since then, histidine or the imidazole group has been widely used for nucleic acid carrier optimization [85-90].

Of course, endosomal escape can be further enhanced by introduction of specific endosomal membrane disrupting or pore forming domains, such poly(vinyl ether) [91] or endosomolytic peptides like melittin or the influenza peptide [92, 93]. Melittin, for instance, a peptide from bee venom consisting of 26 amino acids, is able to enhance transfection efficiency of polycations [12, 94-97] by damaging interactions with the endosomal membrane [98]. As its lytic potential, though, is not pH-selective, various modifications led to specific activation of the lytic activity at acidic pH, thus preventing cytotoxic side effects before internalization [99-102].

Efficient gene carriers like linPEI, though, have the disadvantage that, when applied in vivo, they cannot be degraded and metabolized by the body and accumulation occurs with consequent undesired toxic effects [49, 103]. Therefore, a strategy towards uniting appropriate carrier molecular weight, adequate nucleic acid condensation and cytosolic release for efficient transfection with low toxicity is the design of biodegradable vectors. These are composed of low molecular weight (LMW) monomers linked via degradable bonds resulting in a high molecular weight (HMW) polymer. Triggered by environmental conditions, these polymers are thus chemically programmed to degrade into their LMW non-toxic decomposition products.

There are also different strategies for creating such biodegradable nucleic acid carriers. One possibility is to take advantage of the acidic endosomal environment by introduction of acid-sensitive linkers [63, 104, 105]. Another option is connecting low Mw compounds by hydrolysable linkages, which degrade in a time-dependent manner [106-108]. Furthermore, one can take advantage of the redox difference between oxidizing extracellular and reducing intracellular environment. Chemically incorporated disulfide linkages into polymeric compounds remain therefore relatively stable during blood circulation and can then be cleaved in the cytosol by the reducing agent glutathione (GSH), the most abundantly occurring thiol-source in mammalian cells [109]. Similar to hydrolysable ester-linked polymers, cationic carriers with integrated disulfide bonds can decompose into their smaller molecular weight compounds and therefore release the nucleic acid in the cytosol with lower cytotoxicity than larger non-degradable carriers [110-112]. Polyplex stabilization by
introduction of reducible cross-linking agents before [113] or after [114] complexation with the nucleic acid has also shown promising results in terms of transfection efficiency. This strategy has proven to be even more of advantage also for siRNA delivery [115-117], as siRNA differs from pDNA in size and charge, which makes polyplex stabilization a more crucial feature.

Therefore, it has to be distinguished between vectors for pDNA and vectors for siRNA delivery. As already mentioned, these cargos differ in size and chemical properties and thus efficient pDNA delivery is not a warrant that the same carrier will deliver siRNA in an equally efficient manner.

Consequently, there is need for better defined delivery systems, so as to allow conclusions on structure-activity relationships for the respective nucleic acid and thus provide information for concerted optimization.

1.4 Towards better defined delivery systems

Chemical programming of polymers has proven to be a crucial tool in mimicking virus-like features. Thus, alterations in polymer structure and conformation can be correlated to transfection efficiency and cytotoxicity. It has to be considered: the better the polymer structure is defined, the more detailed study of structure-activity relationships is possible. First approaches towards better defined polymer structure with narrow molecular weight distribution have been made by poly(amo...Estern) [106, 118] and pseudodendrimer synthesis [119]. An additional advantage of these structures is also their biodegradability, which allows high molecular weights for nucleic acid condensation and transfection, but without toxicity, as the carriers decompose into small Mw, nontoxic compounds.

A class of molecules with defined architecture are dendrimers. These are characterized by a relatively low polydispersity due to the synthetic process, whereas stepwise synthesis can be performed by two different methods, divergent or convergent [120-122]. Cationic dendrimers like commercially available polyamidoamine (PAMAM) [123-125] or polypropylenimine (PPI) [126, 127] have already been investigated as nucleic acid carriers. These studies, however, show that there is still room for improvement concerning transfection efficiency and cytotoxicity.

As the synthetic process allows changing the surface character of the dendrimer by introducing specific residues for enhanced gene transfection, several modified
poly(amido amine); PAMAM [128-131] and PPI [132-136] based structures were investigated for DNA and siRNA transfection.

**Fig. 3. Nucleic acid carrier systems.**
Schematic structure of an adenovirus, chemical structures of linear PEI and PPI G2.

Lipidoids are also a class of efficient nucleic acid carriers and Akinc et al. showed a synthetic method of such compounds suitable for combinatorial chemistry. Thus, diverse parallel functionalization and screening of a large lipidoid library allowed fast determination of efficient carriers [137]. Further development of a combinatorial approach of this nucleic acid carrier class was used for the determination of functional group effects on siRNA delivery [138].

The group around J.-P. Behr followed another strategy, namely the generation of monodisperse nucleic acid delivery systems by monomolecular condensation of pDNA with cationic detergents [139-141].

A further possibility of assembling defined nucleic acid carrier systems which bears many advantages is solid-phase peptide synthesis. This synthetic strategy will be introduced in the following section.

### 1.5 Solid-phase peptide synthesis (SPPS) allows assembly of precise, sequence defined nucleic acid carriers

In 1963, R. B. Merrifield published his work on peptide synthesis following a novel strategy, namely the use of an insoluble but porous chloromethylated polystyrene polymer as a solid support for stepwise amino acid assembly [142]. This synthetic method mainly makes use of simple chemical principles: the backbone of amino acids contains a carboxylic acid and a primary amine. Activation of the carboxylic acid enables reaction with a primary amine, resulting in a stable amide bond (**Fig. 4**). Thus, the chain can be elongated in a controlled manner. Accomplishing this reaction
on solid phase has the advantage that excess reagents or by products can be discarded by washing steps. After finishing the desired sequence, the product can be easily cleaved off the solid support and collected by filtration.

**Fig. 4.** Reaction of a primary amine with an activated carboxylic acid to a stable amide bond.

After first difficulties, Merrifield further improved this method himself [143] and since then great advance has been made towards optimization of reaction conditions, such as development of suitable amino acid side chain protection groups in order to prevent undesired side reactions or novel cleavage strategies. Furthermore, adequate analytical and purification methods for the products make SPPS a reliable synthetic method for sequence-defined, precise structures. Also, novel synthetic devices enable using SPPS for combinatorial chemistry, as parallel synthesis of multiple sequences is possible either manually or using automatic peptide synthesizers. Thus, different structural combinations can be generated at the same time.

Due to its many advantages, SPPS was used during the last decades also for the synthesis of precise nucleic acid carriers.

Dendritic structures, for instance, can be easily generated by the introduction of lysines with two primary amines in α- and ε-position as branching points. Using this attribute, 25 years ago J. Tam generated in a single solid-phase synthesis multiple antigenic peptides (MAPs), based on a lysine core matrix and antigenic peptides of 9 – 16 amino acids [144]. Pursuing the aim of efficient nucleic acid delivery, other dendritic structures containing functional amino acids such as histidines as additional buffering domains were synthesized by the group around A. J. Mixson [145-147].

Due to the advantages of SPPS, also cationic lipid-like structures can be generated. Wang et al. created a small library of reversibly polymerizable surfactants using combinatorial solid phase synthetic strategy. These vectors contain a protonable amino head group, two cysteine residues and two lipophilic tails, exhibiting pH-sensitive membrane disruption potential. By hence facilitated endosomal escape, the
surfactants mediated efficient \textit{in vitro} luciferase silencing, comparable with the effectivity of cationic lipids [148].

When thinking of pDNA of siRNA delivery, assembly of poly(amido amines) is an interesting and promising approach, as introduction of longer building blocks containing the buffering diaminoethane motif enhance nucleic acid binding and endosomal escape. Only few reports were published on the application of the SPPS methodology for the synthesis of shorter poly(amido amines), those also without aiming at nucleic acid delivery [149-151].

In 2006, Hartmann et al. designed linear peptidomimetic polymers with poly(amido amine; PAA) as a structural pattern. Dicarboxylates and diamines were stepwise coupled in an alternating manner, thus generating a monodisperse oligopeptide. By exact introduction of functionalities in the linear PAA chain, such as poly(ethylene oxide); PEO, a single component block copolymer was synthesized, thus proving the versatility of the method [152]. PEO modified PAAs were studied in a subsequent work concerning dsDNA complexation and condensation qualities, resulting in clearly defined, non cytotoxic polyplexes [153]. The researcher in their studies applied only rather simple diamine compounds and did not include diaminoethane motifs.

In our laboratory David Schaffert introduced oligoamine building blocks containing the buffering diaminoethane unit. In order to avoid undesired side reactions such as on-resin crosslinking, Schaffert et al. modified the diaminoethane unit containing polyamines with a carboxylic anchor and adequate protection groups, thus making them feasible for solid-phase synthesis. By the means of these artificial oligoamino acids, precise, sequence-defined oligomers could be assembled [154]. In a subsequent publication, cationic oligomers with different topologies and modifications, such as introduction of cysteines and/or lipophilic domains, were designed, showing efficient transfection results for both pDNA and siRNA delivery and allowing conclusion on structure-activity relationships [155].

1.6 Aims of the thesis

In the current thesis, SPPS had to be used for overcoming the drawback of polymer polydispersity combined with maintaining important carrier features such as higher molecular weight, cargo binding properties and the buffering diaminoethane motif. In particular, the SPPS methodology should be used for the design of branched
oligomers, which are supposed to be biocompatible and sequence-defined, using cationic artificial and natural amino acids.

Firstly, branched structures had to be generated directly on solid support by introduction of two subsequent lysines. Due to two primary amines in α- and ε-position of lysine, the generated four amino-groups should act as starting points for four arms which could be elongated in a parallel manner, allowing gain in molecular weight in only few synthetic steps (Fig. 5. A, C, D). Also, the impact of stepwise increase of arm length on cargo binding and delivery should be evaluated. Further modifications of this class of oligomers like the introduction of cysteines for polyplex stabilization, variation in building block length or insertion of histidines as additional buffering domain should bring further insights in structure-activity relationships. The thus generated compounds had to be evaluated not only for their potential for efficient and safe gene delivery, but also for siRNA-mediated gene silencing, so as to determine differences in carrier requirements for the respective nucleic acid.

Secondly, a novel approach towards avoiding toxicity related to higher molecular weight should be also developed, namely assembly of defined biodegradable oligomers for gene delivery. This class of pDNA carriers should consist of the structurally defined dendritic core polypropylenimine with eight primary amines on the surface (PPI G2), which is non-toxic but also does not mediate transfection efficiency. This PPI core had to be modified in so far as to allow linkage of precise, sequence-defined cysteine-containing oligo(ethane amino)amides (Fig. 5 A, B, D) via disulfide bond formation. The disulfide linkages can be cleaved in the reducing cytosolic...
environment, hence allowing the carrier to decompose into its non-toxic, low Mw compounds.
Therefore, due to the sequence control allowed by SPPS and also by the concerted coupling in solution to the PPI core, due to reliable purification and analytical methods, two strategies should be followed for the generation of branched, precise, biocompatible nucleic acid carriers.
The final aim of this thesis is, beyond synthesis of the above mentioned compounds, to gain interesting new insights on structure-activity relationships concerning pDNA and siRNA delivery by biophysical and biological evaluation.
2 MATERIALS AND METHODS

2.1 Chemicals and reagents

Fmoc-Ala-Wang resin Low Load was purchased from Novabiochem (Darmstadt, Germany); pentafluorophenol (Pfp), dicyclohexylcarbodiimide (DCC), 0.5 M tris(2-carboxyethyl)phosphine (TCEP), 2-chloro-1-methylpyridinium iodide (CMPI), (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT), 1-hydroxy-benzotriazol (HOBt), trisisopropylsilane (TIS), Triton X-100, 2-(N-morpholino)ethanesulfonic acid (MES) and 50mM sodium hydroxide solution from Sigma-Aldrich (Munich, Germany); benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and microreactors from MultiSynTech (Witten, Germany).

All amino acids, peptide grade dimethylformamide (DMF), diisopropylethylamine (DIPEA) and trifluoroacetic acid (TFA) were obtained from Iris Biotech (Marktredwitz, Germany). Boc-Cys(NPys)-OH (BCNP) was purchased from Bachem (Bubendorf, Switzerland). Polypropyleneimine (PPI) G2 was obtained from SyMO-Chem (Eindhoven, The Netherlands).

Spectra/Por dialysis membranes were purchased from Carl Roth GmbH (Karlsruhe, Germany).

Linear PEI (linPEI with an average molecular weight of 22kDa) is described in [13]. Plasmid pEGFPLuc (encoding a fusion of enhanced green fluorescent protein EGFP and Photinus pyralis luciferase under control of the CMV promoter) was produced with the Qiagen Plasmid Giga Kit (Qiagen, Hilden, Germany) according to the manufacturer specifications.

Ready to use siRNA duplexes were synthesized and provided by Axolabs GmbH (formerly: Roche Kulmbach, Germany): GFP-siRNA (sense: 5’-AuAucAuGGccGAcAAGcAdTsdT-3’; antisense: 5’-UGCUUGUCGGCcAUGAcAUdTsdT-3’; small letters: 2’methoxy-RNA; s: phosphorothioate) for silencing of the eGFPLuc protein and control-siRNA (sense: 5’-AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense 5’-CuAAuAcAGGCcAAuAcAUdTsdT-3’) as a control.

Water was used as purified, deionized water.
2.2 General methods for SPPS-based oligomer synthesis

2.2.1 Syntheses of cationic building blocks
Cationic building block Stp was synthesized as described in [154]. Gtt was used as described and synthesized by Dr. Naresh Badgujar (Wagner lab) in [154]. New cationic building block Sph was developed and synthesized by Dr. Naresh Badgujar as described in [156].

2.2.2 General methods for oligomers synthesis by manual SPPS

<table>
<thead>
<tr>
<th>Synthetic step</th>
<th>Reagent</th>
<th>Reaction time</th>
<th>Wash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resin swelling</td>
<td>DMF¹</td>
<td>1¹-16² h</td>
<td>1 x DMF¹ (+1% Triton-X 100²)</td>
</tr>
<tr>
<td></td>
<td>DMF + 1% Triton-X 100²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coupling</td>
<td>DMF¹ (+ 1% Triton-X 100²)</td>
<td>1-2 h</td>
<td>4 x DMF¹ (+ 1% Triton-X 100²)</td>
</tr>
<tr>
<td>Fmoc deprotection</td>
<td>20% piperidine in DMF¹</td>
<td>1 x 10, 1 x 20 min¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2% piperidine, 2% DBU in DMF + 1% Triton²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 x DMF¹</td>
<td>6 x DMF¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 x DMF + 1% Triton-X 100²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cleavage</td>
<td>TFA: water 95:5⁴</td>
<td>1-2 h</td>
<td>2 x TFA</td>
</tr>
<tr>
<td></td>
<td>TFA:TIS:water 95:2.5:2.5⁵</td>
<td></td>
<td>2 x DCM</td>
</tr>
<tr>
<td></td>
<td>TFA:TIS:water 92.5:5:2.5³</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ for generation of four-arm core / five-arm Stp tail and subsequent branching / linear oligomer
² for synthesis after four-arm branching
³ for histidine-containing oligomers
⁴ for not cysteine-containing oligomers
⁵ for cysteine-containing oligomers

2.2.3 DMF test on amine impurities
6 µl of a bromophenol blue stock solution (5 mg/ml in DMSO) were added to 1 ml DMF. DMF was accepted for use if the solution color was yellow or slightly green.
2.2.4 Fmoc quantification

5 – 10 mg of dry resin was weighed in duplicates in Eppendorf tubes and agitated with 1.0 ml 20% piperidine in DMF for 1.5 h. Thereafter, the tube was vortexed briefly and the resin was allowed to settle for approximately 2 min. 25 µl of the supernatant of each sample, of a positive control (Fmoc-Ala-Wang resin) and of a blank solution (20% piperidine in DMF) were diluted to 1 ml with DMF. \(A_{301}\) of each sample was determined in duplicates. The Fmoc-substitution (FS) of the resin was calculated using following equation:

\[
FS \text{ (mmol/g)} = \frac{A_{301} \cdot 1000}{m \cdot 7800 \cdot D}
\]

\(A_{301}\): absorbance at \(\lambda = 301\) nm

\(m\): resin mass [mg]

7800: molar extinction coefficient [L mol\(^{-1}\) cm\(^{-1}\)]

\(D\): dilution factor (0.025)

2.2.5 Kaiser Test

Reagent A: 5% ninhydrin in ethanol (w/v)

Reagent B: 80% phenol in ethanol (w/v)

Reagent C: 2 ml 0.001 M KCN in 98 ml pyridine

A few resin beads were taken into an Eppendorf cap and washed three times with DMF and three times with methanol. Two drops of each reagent were added and the beads were heated at 99°C for 4 min. The presence of free amino groups gave a positive test (blue beads), whereas a negative outcome indicated no presence of free amino groups (colorless beads).

2.2.6 Introduction of Triton X-100

In order to avoid intramolecular chain aggregation due to hydrophobic interactions and yield improvement, 1% Triton X-100 was added to the coupling solvent or deprotection solvent mixture used for chain elongation of four- and five-arm oligomers after branching.
2.3 Syntheses of four- and five-arm oligomers

2.3.1 Synthesis of four-arm core

After swelling 0.2 mmol of Fmoc-Ala-Wang resin Low Load (Novabiochem) in DMF and cleavage of the Fmoc protecting group by double treatment with 20% piperidine in DMF, a solution of Fmoc-Lys(Fmoc)-OH (0.4 eq), PyBOP/HOBt (0.4 eq) and DIPEA (0.8 eq) in DMF was added to the resin and the vessel was agitated for 1 h. The unreacted amino groups were subsequently acetylated using 20 equivalents of acetic anhydride and 40 equivalents of DIPEA in DMF before removal of the Fmoc protecting group. The second coupling was performed by adding a solution of Fmoc-Lys(Fmoc)-OH (4 eq), DIPEA (8 eq) and PyBOP/ HOBt (4 eq) in DMF and incubation for 1 h. Reaction progress was monitored by Kaiser test. After completion of the reaction the resin was washed five times with DMF and five times with DCM and dried for 12 h in vacuo. The loading of the resin was determined by spectrophotometric Fmoc-quantification using 20% piperidine in DMF.

2.3.2 Synthesis of four-arm Stp oligomers

The preloaded resin (0.02-0.04 mmol according to Fmoc loading) was swollen overnight in DMF. After the swelling 1% Triton X-100 was added to the DMF for use, and all subsequent steps including washing, coupling and Fmoc-deprotection were performed using this mixture. Fmoc protecting groups were cleaved by six-fold treatment (each 5 min) with 2% piperidine, 2% DBU in DMF/Triton. After washing the resin, a solution of Fmoc-Stp-OH (4 eq), DIPEA (8 eq) and PyBOP/ HOBt (4 eq) in DMF/Triton was added for 90 min. The reaction solvent was drained and the resin was washed five times with DMF. Reaction progress was monitored by Kaiser test. The whole process was repeated depending on the desired sequence. The resin was treated six times (each 5 min) with 2% piperidine, 2% DBU in DMF/Triton in order to deprotect the Fmoc group. The resin was washed five times with DMF and five times with DCM and dried over KOH in vacuo. For cleavage the resin was suspended in a solution of TFA/H\textsubscript{2}O (95/5, v/v) and agitated for 3 h. The cleavage solution was drained and collected. The resin was was washed twice with TFA and twice with DCM. The collected solutions were concentrated under reduced pressure to minimum volume. The residue was washed twice with ice-cold MTBE, then dissolved in water and lyophilized. The lyophilized product was dissolved in a minimal volume 10mM HCl and dialyzed against 10 mM HCl using a Spectra/Por\textsuperscript{®} Dialysis Membrane,
MWCO 3500 Da. After 16 h the buffer was exchanged and the dialysis proceeded for another 8 h. The sample was lyophilized and characterized via cation exchange chromatography.

2.3.3 Synthesis of terminally modified four-arm Stp, Gtt and Sph oligomers

Oligomers were synthesized as described above. Additionally, depending on the sequence, either Boc-Cys(Trt)-OH or Boc-Ala-OH was coupled as last amino acid in the same manner. For cleavage the resin was suspended in a solution of TFA/TIS/H$_2$O (95:2.5:2.5, v/v/v) for cysteine containing oligomers, or TFA/H$_2$O (95:5, v/v) for alanine containing oligomers, and agitated for 2 h. The cleavage solution was drained and collected. The resin was washed twice with TFA and twice with DCM. The collected solutions were concentrated under reduced pressure to approximately 2 ml. The product was precipitated in a 1:1 mixture (40 ml) of cooled (0 °C) MTBE and n-hexane and centrifuged at 4 °C for 5 min (3000 rpm). The pellet was then dissolved in 10mM HCl containing 30% acetonitrile and purified by size exclusion chromatography (SEC). Product fractions were pooled and freeze dried. Identity was confirmed by $^1$H-NMR. Purity of selected oligomers was determined by RP-HPLC.

2.3.4 Synthesis of five-arm Stp oligomers

After swelling 0.1 mmol of Fmoc-Ala-Wang resin Low Load (Novabiochem) in DMF and cleavage of the Fmoc protecting group by double treatment with 20% piperidine in DMF, a solution of Fmoc-Stp-OH (0.5 eq), PyBOP/HOBt (0.5 eq) and DIPEA (1.0 eq) in DMF was added to the resin and the vessel was agitated for 1 h. The unreacted amino groups were subsequently acetylated using 20 equivalents of acetic anhydride and 40 equivalents of DIPEA in DMF. Reaction progress was monitored by Kaiser test. After completion of the reaction the resin was washed five times with DMF and five times with DCM and dried for 12 h in vacuo. The loading of the resin was determined by spectrophotometric Fmoc-quantification using 20% piperidine in DMF.

The preloaded resin (0.01 mmol) was swollen in DMF for 1 h. After cleavage of the Fmoc protecting group by double treatment with 20% piperidine in DMF, a solution of Fmoc-Stp-OH (4 eq), PyBOP/HOBt (4 eq) and DIPEA (8 eq) in DMF was added to the resin and incubated for 1 h. In the next two coupling steps Fmoc-Lys(Fmoc)-OH was used as described above, 4 eq for the first coupling and 8 eq for the second.
After removal of the Fmoc protection group with 20% piperidine in DMF, the synthesis was carried on according to the synthesis of four-arm oligomers, using 16 eq building block and amino acid, 16 eq HOBT/PyBop and 32 eq DIPEA in each coupling step. In the last coupling step Boc-Cys(Trt)-OH was used. Cleavage from the resin and further purification was performed as described above.

### 2.3.5 Synthesis of histidine-containing four-arm oligomers

Oligomers were synthesized as described above, with the following modifications: Fmoc-His(Trt)-OH was used as an additional amino acid. Fmoc-deprotection cycles were increased to eight times five minutes. Cleavage from the resin was performed with TFA/TIS/H₂O (92.5/5/2.5, v/v/v). Compounds 582 and 584 (based on [146]) were synthesized automatically using a SyroWAVE Peptide synthesizer (Biotage Sweden AB, Uppsala, Sweden). Couplings were performed 2 x 5 min using a microwave device, deprotection steps were performed using 20% piperidine, 2% DBU in DMF for 3 x 20 min. Cleavage, purification, and characterization were performed as described above.

### 2.3.6 Synthesis of linear Stp oligomers

A Fmoc-Cys(Trt)-Wang resin was preswollen in DMF for 1 h. Fmoc-deprotection was performed by double treatment with 20% piperidine in DMF. After washing the resin five times with DMF, a solution of Fmoc-Stp-OH (4 eq), PyBOP/HOBT (4 eq) and DIPEA (8 eq) in DMF was added to the resin and the vessel was agitated for 1 h. Reaction progress was monitored by Kaiser test. The procedure was repeated, depending on the sequence, up to four times. After the last Fmoc-deprotection, the resin was washed five times with DMF, five times with DCM and dried over night in vacuo. Cleavage from the resin was performed by treatment with TFA/TIS/H₂O (92.5/2.5/2.5, v/v/v) for two hours. The cleavage solution was then drained and collected; the resin was washed twice with TFA and twice with DCM. The collected solutions were concentrated to approximately 1 ml and precipitated in ice-cold MTBE/n-hexane (1/1). After centrifugation, the pellet was washed with ice-cold MTBE. The product was then dissolved in water and freeze dried. Identity was confirmed by ¹H-NMR.
2.3.7 Synthesis of Boc-Cys(NPys)-pentafluorophenyl ester (BCNP-OPfp)

BCNP-OPfp was synthesized according to [157] with slight modifications. 500 mg Boc-Cys(NPys)-OH (1.33 mmol) and 269.3 mg pentafluorophenol (Pfp, 1.463 mmol, 1.1 eq) were suspended in 5 ml DCM. 1 eq dicyclohexylcarbodiimide (DCC, 274.4 mg) was dissolved in 1 ml DCM and added to the solution. The mixture was stirred for 15 min at 0°C and subsequently for 3.5 h at room temperature. After cooling the solution to 0°C, precipitated dicyclohexylurea (DCU) was filtered and the solvent evaporated. Completion of the reaction was monitored by TLC ($R_f$ in ethylacetate: BCNP: 0; Pfp: 0.6, sample: 0.8; in chloroform/methanol 3:1: BCNP: 0.2, Pfp: 0.8, sample: 0.9).

Yield: 650 mg (90%)

2.3.8 Synthesis of activated PPI core (PPI-CNPNP)

30 mg PPI G2 (0.039 mmol) was dissolved in 1 ml DCM. 588.4 mg Boc-Cys(NPys)-OPfp (28 eq, 1.087 mmol) was dissolved in 5 ml DCM and added to the PPI solution. The mixture was stirred for 24 h at room temperature. The solvent was concentrated to a minimal volume and precipitated in ice-cold MTBE. After centrifugation and decantation of the supernatant, the residue was washed with ice-cold MTBE and the procedure repeated until the washing solution was colourless. The residue was then dissolved in acetonitrile, freeze dried and analyzed by $^1$H-NMR.

Yield: 108 mg (46%)

$^1$H-NMR: $\delta$ (ppm) = 1.4-1.5 (s, 72 H, -CH$_3$ boc), 1.6-1.7 (m, 28 H, -CH$_2$-CH$_2$-CH$_2$- PPI), 2.4-3.3 (m, 68 H, $\beta$H cysteine, PPI), 4.3 (t, 8 H, $\alpha$H cysteine), 7.5 (dd, 8 H, $J$=4.7, 8.3 Hz, -CH=CH$_{\text{NPys}}$-CH=), 8.6 (dd, 8 H, $J$=1.6, 8.2 Hz, -CH$_{\text{NPys}}$-C(NO$_2$)=), 8.9 (dd, 8 H, $J$=1.5, 4.7 Hz, -CH$_{\text{NPys}}$=N-)

3.3 (s, MeOD), 4.9 (s, H$_2$O)

In order to remove the boc protection group the precipitate was dissolved in 1 ml 80% TFA in DCM. After 2 h the solvent was evaporated, the residue was dissolved in water and freeze dried. The product was subsequently analyzed by $^1$H-NMR to ensure complete boc removal and for quantification of the NPys-groups. Additionally, surface modification was quantified spectrophotometrically. Purity was determined by RP-HPLC.

$^1$H-NMR: $\delta$ (ppm) = 1.6-2.4 (m, 28 H, -CH$_2$-CH$_2$-CH$_2$- PPI), 3.1-3.6 (m, 68 H, $\beta$H cysteine, PPI), 4.2 (t, 8 H, $\alpha$H cysteine), 7.5 (dd, 8 H, $J$=4.7, 8.3 Hz, -CH=CH$_{\text{NPys}}$-
2.3.9 Assembly of PPI conjugates

PPI-CNP was reacted with 24 eq of linear cationic polymer (related to SH-groups) in a minimal amount of reaction buffer (MES pH 6.1 + 20% acetonitrile). After 4 h the amount of released nitropyridinethione was measured spectrophotometrically. After completion of reaction the sample was transferred to a dialysis tube with an adequate MWCO and dialyzed in water pH 5.5 (acetic acid) for 4 h. After buffer exchange dialysis was continued for additional 20 h. The sample was then freeze dried and analyzed by $^1$H-NMR.

2.4 Methods and devices for compound purification and chemical characterization

2.4.1 Dialysis

Dialysis was performed using SpectraPor tubes of an adequate MWCO. Dialysis was performed in water for four-arm Stp oligomers and in water pH 5.5 for PPI conjugates at 4 °C with buffer exchange after 4 h and total dialysis time of 24 h.

2.4.2 Size exclusion chromatography

Size exclusion chromatography of all polymers was run on an Äkta Basic HPLC system using a self-packed Sephadex G-10 column (GE Healthcare). The buffer used was 10 mM HCl + 30% acetonitrile at a flow rate of 2 ml/min and isocratic elution. The product fractions were pooled and freeze dried.

2.4.3 Analytical ion exchange chromatography (IEX-HPLC)

Analytical IEX-HPLC was performed using an ÄKTA Basic system (GE Healthcare) and a Resource S 1 mL column. Buffer A: 10 mM HCl. Buffer B: 10 mM HCl + 3 M NaCl. Flow rate 2 ml/min. Gradient: 2% B to 100% B in 15 min. UV detection at 214 nm and 280 nm.

2.4.4 Analytical reversed phase HPLC (RP-HPLC)

Analytical RP-HPLC was performed using a Waters HPLC System containing a P-900 gradient pump system under the control of the Millenium software and a C$_{18}$-RP analytical column (Waters SunFire C$_{18}$, 4.6 x 150 mm). Buffer A: H$_2$O + 0.1% TFA,
buffer B: acetonitrile + 0.1 % TFA at a flow rate of 1 ml/min. The gradient was run from 5% to 100% buffer B in 20 min. Absorption of the amide bond was monitored at \( \lambda = 214 \) nm with a 996 Photodiode array detector.

2.4.5 \(^1\)H-NMR

\(^1\)H NMR spectra were recorded using a Jeol JNMR-GX 400 (400 MHz) or JNMR-GX 500 (500 MHz) device. Chemical shifts are reported in ppm and refer to the solvent as internal standard. Data are reported as s=singlet, d=doublet, t=triplet, m=multiplet; integration was performed manually. The spectra were analyzed using NUTS (2D professional version 20020107 by Acron NMR, 2002) or MestreNova (Ver. 5.2.5-4119 by MestReLab Research).

2.4.6 Mass Spectrometry

MALDI-MS analysis was carried out on a Bruker Autoflex MALDI-TOF system.

2.4.7 3-Nitro-2-pyridinesulfenyl (NPys) quantification

A standard Boc-Cys(NPys)-OH (BCNP) solution was serially diluted in methanol and measured spectrophotometrically at 340 nm. The sample was diluted accordingly and measured against methanol as a blank. Concentration of NPys was calculated via the calibration curve.

2.4.8 Quantification of 3-Nitro-pyridine-2-thione (NPythione)

For the calibration curve, a standard BCNP solution was serially diluted in MES buffer:acetonitrile 4:1 and measured spectrophotometrically at 440 nm. Subsequently, the dilutions were treated with 4 µl TCEP (500 µmol/ml) each and incubated at room temperature for 30 min. The released NPythione was measured at 440 nm against the buffer mixture as a blank. The sample was diluted and treated accordingly. Concentration of the released NPythione was calculated after subtraction of the absorption values of untreated BCNP via the calibration curve.

2.4.9 Ellman`s assay [158]

The colorimetric reaction between Ellman’s reagent (5,5'-dithiobis(2-nitrobenzoic acid), DTNB) and the free thiol groups was performed as follows: 0.4 mg DTNB dissolved in 1 ml of Ellman’s buffer (0.2 M Na\(_2\)HPO\(_4\) with 1 mM EDTA at pH 8.0) was used as stock solution. Standard cystein solution and samples were serially diluted in Ellman’s buffer and 10% (v/v) of the stock solution. After 20 minutes
incubation at 37 °C the solutions were measured at 412 nm. Ellman´s stock diluted 1:10 in Ellman´s buffer was taken as blank. Concentration of the thiol group was calculated via the calibration curve.

2.4.10 Tris(2-carboxyethyl)phosphine (TCEP) assay
A standard cysteine solution (0.05 µmol/ml) was serially diluted with Ellman´s buffer and incubated with 40 µl TCEP (5 µmol/ml) for 10 min at room temperature. Subsequently, 10 µl 2-chloro-1-methylpyridinium iodide (CMPI, 100 µmol/ml) were added and further incubated for 10 min at 37°C. Absorbance was measured at 314 nm with buffer/TCEP/CMPI mixture as a blank. Concentration of reduced disulfide bonds and resulting free thiols was calculated via the calibration curve.

2.5 Biophysical and biological characterization

2.5.1 Acidimetric titrations of histidine containing oligomers
The protonation behaviour was investigated over a pH range of pH 2 to 11. The titrations were carried out with an automated potentiometric titrator Metrohm Titrando 905 equipped with a Biotrode pH electrode (METROHM GmbH & Co. KG, Filderstadt, Germany). The oligomer amount corresponding to 15 µmoles protonable amines was dissolved in 3.5 ml 50 mM sodium chloride solution. The pH was adjusted < 2 with 0.5 M hydrochloric acid. Titrations were carried out with 50 mM sodium hydroxide solution until the endpoint of pH 11 was reached. To distinguish polymer and solvent effects a control titration of 50 mM sodium chloride solution without polymer was performed. Volume differences (ΔV) from pH 2 to 11 and pH 5.5 to 7.4 (endosomal pH range) were determined. Buffer capacity was calculated according to the following formula:

\[
Buffer\ Cap[\%]=\left(\frac{\Delta V(pH\ 5.5-7.4\ sample)}{\Delta V(pH\ 5.5-7.4\ NaCl)\ \text{ml}\ast 50\ \mu\text{moles/ml}}\right)\ast 100
\]

2.5.2 Polyplex formation
Polyplex formulations for transfection and binding assay experiments were prepared as follows: 200 ng of DNA or 500 ng of siRNA and the corresponding amount of polymer were diluted in separate tubes in 10 µL of 20 mM HEPES buffered 5%
glucose pH 7.4 (HBG) each. The polycation solution was added to the nucleic acid, mixed and incubated for 30-40 min at room temperature.

2.5.3 Measurement of particle size and zeta potential
Particle size and zeta potential of pDNA and siRNA formulations were measured by laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, U.K.). PDNA and siRNA polyplexes were prepared in HBG pH 7.4, whereas siRNA polyplexes were diluted in 20 mM HEPES prior to measurement.

2.5.4 pDNA binding assay
A 1% agarose gel was prepared by dissolving agarose in TBE buffer (trizma base 10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g, and 1 l of water) and boiling it up to 100 °C. After cooling down to about 50 °C and addition of GelRed, the agarose gel was casted in the electrophoresis unit. Polyplexes containing 200 ng of pDNA in 20 µL HBG and loading buffer (prepared from 6 ml of glycerine, 1.2 ml of 0.5 M EDTA, 2.8 ml of H2O, 0.02 g of bromophenol blue) were placed into the sample pockets. Electrophoresis was performed at 80 V for 80 min.

2.5.5 siRNA binding assay
A 2.5% agarose gel was prepared containing GelRed as described above. Polyplexes containing 500 ng of siRNA in 20 µl HBG and loading buffer (containing xylene cyanol) were placed into the sample pockets. Electrophoresis was performed at 80 V for 40 min.

2.5.6 pDNA polyplex dissociation assay
An agarose gel was prepared as for pDNA binding assay. Polyplexes were formed and incubated for further 30 min with 0.1, 0.2 and 0.4 I.U. heparin, with TCEP (0.5 M, 0.5 µl) and with 0.2 I.U. heparin and TCEP. Electrophoresis was run as described above.

2.5.7 Ethidium bromide exclusion assay
Polymer ability to bind pDNA and siRNA was evaluated by an ethidium bromide (EtBr) exclusion assay. The effect of stepwise addition of polymer solution to 10 µg pDNA or siRNA in 1 ml HBG containing 0.4 µg EtBr was measured at increasing N/P ratios using a Cary Eclipse spectrophotometer (Varian, Germany). Maximal
fluorescence intensity was set 100% for the EtBr solution containing free nucleic acid and fluorescence decrease was measured after each addition of polymer aliquot.

2.6 Cell culture

Mouse neuroblastoma cells Neuro2A and Neuro2A/EGFPLuc cells, stably expressing the CMV-EGFPLuc cassette (Clontech) encoding a fusion of enhanced green fluorescent protein and GL3 firefly luciferase under the control of the CMV promoter as described in [159], were grown in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FCS, 4 mM stable glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin.

2.6.1 Luciferase reporter gene expression

Neuro2A cells were seeded 24 h prior to pDNA delivery using 10000 cells per well in 96-well plates. In vitro transfection efficiency of the polymers was evaluated using 200 ng pEGFPLuc encoding plasmid per well. All experiments were performed in quintuplicates. Before transfection, medium was replaced with 80 μL fresh medium containing 10% FCS. Polyplexes formed at different protonable nitrogen/phosphate (N/P) ratios in 20 μL HBG were added to each well and incubated at 37 °C. At 24 h after transfection, cells were treated with 100 μL cell lysis buffer (25 mM Tris, pH 7.8, 2 mM EDTA, 2 mM DTT, 10% glycerol, 1% Triton X-100). Luciferase activity in the cell lysate was measured using a luciferase assay kit (100 μL Luciferase Assay buffer, Promega, Mannheim, Germany) and a Lumat LB9507 luminometer (Berthold, Bad Wildbad, Germany).

2.6.2 Cell viability assay (MTT assay)

Neuro2A cells were seeded into 96-well plates at a density of $1 \times 10^4$ cells/well. After 24 h, culture medium was replaced with 80 μL fresh growth medium containing 10% FCS and transfection complexes (20 μL in HBG) at different N/P ratios were added. All studies were performed in quintuplicates. 24 h post transfection, 10 μl MTT (5 mg/ml) were added to each well reaching a final concentration of 0.5 mg MTT/mL. After an incubation time of 2 h, unreacted dye and medium were removed. Optical absorbance was determined at 590 nm (reference wavelength 630 nm) using a micro plate reader (Spectrafluor Plus, Tecan Austria GmbH).
2.6.3 Luciferase gene silencing

Gene silencing experiments were performed in Neuro2A/EGFPLuc cells stably expressing the CMV-EGFPLuc cassette (Clontech) encoding a fusion of enhanced green fluorescent protein and GL3 firefly luciferase under the control of the CMV promoter as described in [159] The cells were grown as described above. For transfection either GFP-siRNA for silencing of the EGFPLuc protein, or control-siRNA as a control were used at a concentration of 0.5µg/well each. SiRNA delivery was performed in 96-well plates with 5000 cells per well in triplicates. Cells were seeded 24 h prior to transfection and then medium was replaced with 80 µL fresh growth medium containing 10% FCS. Transfection complexes for siRNA delivery (20 µL formed in HBG) at different N/P ratios were added to each well and incubated at 37 °C. At 48 h after transfection, luciferase activity was determined as described above. The relative light units (RLU) were presented as percentage of the luciferase gene expression obtained with only buffer treated control cells.
3 RESULTS

3.1 Four- and five-arm oligo(ethanamino)amides for pDNA and siRNA delivery

3.1.1 Introduction
Linear PEI with an average molecular weight of 22kDa is often termed the `gold standard’ for gene delivery. It has outstanding properties concerning pDNA binding and transfection [76] not only due to its chemical structure containing the `proton sponge’ 1,2-diaminoethane motif [77], but also due to its high molecular weight. Nevertheless, its polydispersity hampers precise conclusions on structure-activity relationships.

In order to overcome this drawback, SPPS was used as synthetic tool for the generation of precise branched oligomers. Lysine, due to two primary amines per amino acid in α- and ε- positon, offers the possibility for assembly of branched structures (Scheme 1). By subsequent coupling of two lysines, four arms can be elongated in a parallel manner with the corresponding building blocks or amino acids. Thus, increase in molecular weight in only few synthetic steps is facilitated.

Scheme 1. Lysine as branching point

For the generation of four- and five-arm oligomers, different artificial amino acids containing the 1,2-diaminoethane motif were used (Fig. 6 A). The cationic building block Fmoc-Stp(boc)₃-OH with three protonable amino groups was first developed and synthesized by Dr. David Schaffert in the Wagner lab [154]. Dr. Naresh Badgujar (Wagner lab) similarly developed and synthesized two further building blocks which were used in this thesis, namely the shorter Fmoc-Gtt(boc)₂-OH with two [154] and the new, longer building block Fmoc-Sph(boc)₄-OH with four protonable amino groups (Fig. 6 A). All building blocks consist of an oligoamine unit with protonable secondary amines, a terminal primary amine and a carboxylic handle for coupling.
The building block unit was abbreviated with three letters as follows:

<table>
<thead>
<tr>
<th>Carboxylic handle</th>
<th>Oligoamine unit</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutaroyl-</td>
<td>triethylentetraamine</td>
<td>Gtt</td>
</tr>
<tr>
<td>Succinoyl-</td>
<td>tetraethylpentamine</td>
<td>Stp</td>
</tr>
<tr>
<td>Succinoyl-</td>
<td>pentaethylenhexamine</td>
<td>Sph</td>
</tr>
</tbody>
</table>

All reactive sites were protected with adequate groups (Fig. 6 A, C) in order to avoid undesired side reactions. Boc is acid-labile, whereas Fmoc can be cleaved under basic conditions, setting free the primary amine for subsequent coupling on solid phase.

The natural amino acids used in SPPS in this thesis (Fig. 6 B) bear also adequate side chain protection groups. Trt for thiol protection within the amino acid cysteine is, similar to boc, cleavable under acidic conditions (Fig. 6 B, C).

**A**

Fmoc-Gtt(boc)₂-OH

Fmoc-Stp(boc)₂-OH

Fmoc-Sph(boc)₄-OH

**B**

Fmoc-Lys(Fmoc)-OH  Boc-Cys(Trt)-OH  Boc-Ala-OH

**C**

Fig. 6. (A) Protected building blocks Gtt, Stp and Sph. The protection groups boc and Fmoc can be cleaved in an orthogonal manner, i.e. boc is stable under basic conditions and Fmoc is stable under acidic conditions. Fmoc is cleaved during synthesis for chain elongation; boc and Trt are cleaved simultaneously with the finished sequence from the solid support under acid treatment. (B) Structures of the used protected natural amino acids. (C) Structures of the used protection groups.
After completion of the desired sequence, the generated oligomer was cleaved off the solid support by acid treatment. Simultaneously, also the acid-labile protection groups were cleaved and the desired product was collected by filtration.

In contrast to the convention of writing peptide sequences from N → C terminus, the sequences of the described oligomers in this thesis are shown from C → N terminus. Amino acids were abbreviated according to the one-letter code:

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>One-letter-code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine</td>
<td>A</td>
</tr>
<tr>
<td>Cysteine</td>
<td>C</td>
</tr>
<tr>
<td>Lysine</td>
<td>K</td>
</tr>
</tbody>
</table>

3.1.2 General synthesis and library design

Monomers were assembled using standard amide bond formation between terminal amino groups and activated carboxylic groups of the next building block. Alanine-loaded resin was modified with bis-Fmoc-lysine. Repetition of this step generated four amino groups which were elongated into four arms with the building blocks (BB) Stp, Gtt, or Sph, and in the last step with cysteine or alanine (C/A) (Scheme 2). For the generation of five-arm oligomers, a building block tail was introduced before lysine branching.

Scheme 2. Schematic representation of four-arm generation and oligomer synthesis.

An alanine preloaded resin was modified with bis-Fmoc-lysine, thus generating four arms. Subsequently, cationic building blocks were reacted and, depending on the sequence, terminal cysteines or alanines.
After cleavage from the solid support, the oligomers provide a carboxylic end (C-terminus) and four N-terminal primary amines (Fig. 7). By these means, a small library of various four- and five-arm oligomers was generated (Fig. 7, left panel), first using Stp with three protonable amines as building block. Different chain lengths and thus increasing molecular weight were tested for Stp oligomers, starting with one up to five building blocks per arm. Subsequently, terminal cysteines were introduced for polyplex stabilization by intramolecular disulfide formation. Furthermore, as Stp was not the only available building block suitable for solid-phase synthesis, for the most efficient oligomers Stp was replaced with two further building blocks: on the one hand the shorter Gtt with only two, on the other hand the longer Sph with four protonable amines (Fig. 7, right panel). By this variation, conclusions could be drawn on the impact of the length of the diaminoethane unit on cargo binding and delivery.

**Fig. 7. Library design of four- and five-arm oligomers** containing different building blocks and terminal cysteine or alanine modification.

All oligomers were purified by either by dialysis (unmodified Stp oligomers) or SEC in order to remove residual scavengers or small molecular weight impurities. **Fig. 8** shows exemplary analytical IEX (unmodified Stp oligomers) and RP-HPLC traces of selected compounds. No significant impurities could be observed. Further analytical IEX traces of unmodified Stp compounds are shown in Appendix 7.3.
3.1.3 Four-arm Stp oligomers for pDNA delivery

First, the cationic building block Stp was used for the generation of four-arm gene carriers with increasing arm length up to five Stp/arm.

Measurements on particle size and surface charge of pDNA polyplexes (Fig. 9 A) show that with increasing N/P ratio (i.e. molar ratio of protonable nitrogens to phosphates) the particle size decreases due to higher charge density, whereas oligomers with 5 Stp/arm complex pDNA to the smallest particle size. Oligomers with only 1 Stp/arm are not able neither to form measurable particles, nor to compact pDNA efficiently so as to result in positive surface charge. Starting with 2 Stp/arm, all particles display a positive zeta potential.

The binding efficiency of unmodified Stp oligomers to pDNA was evaluated by agarose gel electrophoresis (Fig. 9 B). This assay displays the effect of increasing amount of building block/arm. The longer the sequence, the stronger also the binding
of the cargo, whereas oligomers with 1 Stp/arm did not bind pDNA at all and starting with three Stp/arm pDNA is fully bound at all N/P ratios.

### A

<table>
<thead>
<tr>
<th>Oligomer</th>
<th>N/P</th>
<th>Mean Size [nm]</th>
<th>Mean PDI</th>
<th>Mean Zeta Potential [mV]</th>
</tr>
</thead>
<tbody>
<tr>
<td>286 Stp1</td>
<td>3</td>
<td>762 ± 33</td>
<td>0.32 ± 0.04</td>
<td>-7.1 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>n.d.</td>
<td>-</td>
<td>0.6 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>n.d.</td>
<td>-</td>
<td>2.7 ± 0.2</td>
</tr>
<tr>
<td>287 Stp2</td>
<td>3</td>
<td>605 ± 35</td>
<td>0.35 ± 0.05</td>
<td>10.6 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>515 ± 51</td>
<td>0.28 ± 0.01</td>
<td>13.6 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>337 ± 52</td>
<td>0.17 ± 0.02</td>
<td>16.0 ± 0.4</td>
</tr>
<tr>
<td>288 Stp3</td>
<td>3</td>
<td>188 ± 4</td>
<td>0.07 ± 0.02</td>
<td>19.1 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>160 ± 1</td>
<td>0.09 ± 0.02</td>
<td>17.7 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>296 ± 3</td>
<td>0.13 ± 0.03</td>
<td>14.1 ± 0.6</td>
</tr>
<tr>
<td>289 Stp4</td>
<td>3</td>
<td>143 ± 2</td>
<td>0.12 ± 0.03</td>
<td>17.9 ± 0.8</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>123 ± 10</td>
<td>0.13 ± 0.02</td>
<td>23.2 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>232 ± 2</td>
<td>0.04 ± 0.01</td>
<td>16.4 ± 0.4</td>
</tr>
<tr>
<td>403 Stp5</td>
<td>3</td>
<td>102 ± 1</td>
<td>0.11 ± 0.02</td>
<td>25.0 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>90 ± 2</td>
<td>0.14 ± 0.02</td>
<td>20.6 ± 0.3</td>
</tr>
</tbody>
</table>

n.d.: not detectable

### B

Fig. 9. (A) Particle size and zeta potential of Stp oligomers/pDNA polyplexes at increasing N/P ratios. (B) pDNA binding assay of Stp oligomers at different N/P ratios.

Four-arm Stp oligomers were tested *in vitro* on Neuro2A cells on their efficiency as gene carriers by Thomas Fröhlich (Wagner lab). **Fig. 10, upper panel**, shows the results of the luciferase reporter gene assay. Oligomers with one or two building blocks/arm did not have any effect, whereas starting with three Stp/arm gene delivery efficiency increases. Nevertheless, a maximum in efficiency is achieved with compound **289** containing four Stp/arm; a longer chain does not show any further benefit. Furthermore, even the best compounds showed only a moderate transfection...
efficiency compared to `gold standard` linPEI. No negative effects on cell metabolic activity could be observed in the MTT assay, though (Fig. 10, lower panel).

![Graph](image)

Fig. 10. Luciferase reporter gene assay of four-arm Stp oligomers at increasing N/P ratios and corresponding cell viability data below (experiment performed by Thomas Fröhlich, Wagner lab).

Therefore, as these oligomers left room for optimization in terms of gene delivery, cysteines were introduced as activity enhancing amino acids.

### 3.1.4 Effect of introduction of cysteines

As cysteines are known to be able to stabilize polyplexes by cross-linking due to disulfide bond formation, these amino acids were introduced at the N-terminus of Stp oligomers with 2-5 building blocks/arm and evaluated biophysically and biologically. Alanines were used as control amino acid in order to exclude possible effects due to arm elongation.

The strength of the electrostatic interaction between cationic Stp oligomers and negatively charged pDNA was investigated by agarose gel electrophoresis (Fig. 11 A). At first, oligomers were pre-incubated with pDNA at room temperature in air-saturated buffer to allow (in the case of cysteine-containing oligomers) oxidative disulfide formation after initial complex formation as described [155]. All Stp
oligomers showed good pDNA binding abilities, independent of cysteine modification. Transfections (performed by Petra Kos, Wagner lab) demonstrated that the presence of terminal cysteines has a very positive impact on luciferase gene transfer (similar efficiency as LinPEI), whereas chain length is a less important feature (Fig. 11 B, upper panels). Optimal efficiency is reached with cysteine modified four-arm Stp oligomers 392 and 402 with three and four Stp units per arm, respectively. 421 with five Stp per arm shows no further improvement. The alanine-ended mutants are by far not as effective as the cysteine oligomers. pDNA polyplexes were well tolerated by cells even at high N/P ratios (Fig. 11 B, lower panels).

As the standard binding assay did not disclose differences in pDNA binding affinity, a polyplex dissociation assay was carried out (Fig. 11 C). Oligomers were incubated with pDNA under oxidative conditions and then treated with different concentrations of heparin to challenge electrostatic interactions between cationic carrier and negatively charged cargo. In parallel, polyplexes were also treated with TCEP for cleavage of formed disulfide bonds, and with both TCEP and heparin at a medium dose. Agarose gel electrophoresis (Fig. 11 C) after treatment with heparin at increasing concentrations showed that polyplexes formed with cysteine-modified oligomers are more stable than the alanine mutants. Low dose heparin dissociates all alanine but none of the cysteine containing structures. At medium heparin dose, cysteine containing polyplexes with four Stp units per arm are more stable than those with three Stp units. The effect of combined heparin/TCEP treatment can be seen best for polyplex formed with oligomer 402. It is stable under single treatment with each heparin or TCEP, but the cargo is released when both reagents are present.
Fig. 11. (A) pDNA binding assay of cysteine- and alanine-modified four-arm Stp oligomers. (B) Luciferase gene transfer (Neuro2A cells) and corresponding metabolic cell activities below (experiment performed by Petra Kos, Wagner lab). (C) pDNA polyplex dissociation assay of four-arm Stp oligomers. Polyplexes were formed at N/P 12 and treated as follows: lane 1: polyplex, 2: polyplex + 0.1 I.U. heparin, 3: polyplex + 0.2 I.U. heparin, 4: polyplex + 0.4 I.U. heparin, 5: polyplex + TCEP, 6: polyplex + TCEP + 0.2 I.U. heparin.
3.1.5 Effect of Stp replacement by shorter building block Gtt

Next, the shorter triethylene tetramine-based building block Gtt was used for assembly of analogs of the most efficient Stp oligomers with three and four building blocks/arm. Only the cysteine-modified Gtt oligomers formed oligomer/pDNA complexes stable in the electrophoretic binding assay (Fig. 12 A, left panel); the alanine mutants did not bind pDNA effectively, as shown by the laddering in Fig. 12 A, right panel. This is the result of either not completely bound pDNA or polyplex instability during electrophoresis. Consistently, only Gtt3-C (492) and Gtt4-C (494) mediated luciferase gene transfer (Fig. 12 B), whereas the alanine-modified Gtt four-arms displayed even lower activity than the alanine-modified Stp four-arms (experiment performed by Petra Kos, Wagner lab).

Fig. 12. (A) pDNA binding assay of cysteine- and alanine modified Gtt oligomers. (B) Luciferase assay and corresponding cell metabolic activities (experiment performed by Petra Kos, Wagner lab).
3.1.6 Effect of Stp replacement by longer building block Sph

The new building block Sph (with one additional amino ethane unit) was applied in assembly of oligomers with three and four building blocks per arm and N-terminal cysteines or alanines. Sph oligomers did bind their cargo very efficiently independent of end-modification (Fig. 13 A). A polyplex dissociation assay (Fig. 13 B) confirms the stabilizing effect of the cysteines.

Fig. 13. (A) pDNA binding assay of cysteine-/alanine-Sph oligomers. (B) Dissociation assay of polyplexes (N/P 12) treated as follows: lane 1: polyplex, 2: polyplex + 0.1 I.U. heparin, 3: polyplex + 0.2 I.U. heparin, 4: polyplex + 0.4 I.U. heparin, 5: polyplex + TCEP, 6: polyplex + TCEP + 0.2 I.U. heparin.

Biological evaluation of polyplexes displayed the superiority of the Sph building block in terms of luciferase reporter gene transfer and no notable cytotoxicity even at high N/P ratios (Fig. 14 A, experiment performed by Petra Kos, Wagner lab). The alanine-ended oligomers showed equal transfection efficiency as linPEI, the cysteine modified compounds were even up to 60-fold more efficient than linPEI.

The cysteine-ended four-arms Gtt4-C, Stp4-C and Sph4-C were compared in their pDNA compaction ability in an ethidium bromide exclusion assay (Fig. 14 B). When a polycation binds and compacts pDNA, the intercalator fluorescence is significantly reduced. LinPEI was used as a control with high compaction activity. This assay shows that Sph oligomers were the most potent in terms of pDNA compaction ability, whereas Gtt oligomers do not compact pDNA efficiently.
Fig. 14. (A) Luciferase gene transfer and corresponding metabolic cell activities (experiment performed by P. Kos). (B) Ethidium bromide exclusion assay of cysteine-modified oligomers of different building blocks (4 units per arm).
Particle sizes and zeta potential of four-arm polyplexes are listed in Table 1. Zeta potential obtained with cysteine-modified four-arms Gtt4-C, Stp4-C and Sph4-C (all with 4 units per arm) were around +25 mV. Particles sizes of 496 nm, 367 nm and 258 nm, respectively, however clearly differed and indicated a correlation of pDNA compaction with aminoethane numbers in the building block.

<table>
<thead>
<tr>
<th>Oligomer Id</th>
<th>Sequence</th>
<th>Mean Size [nm]</th>
<th>Mean Pdl</th>
<th>Mean Zeta Potential [mV]</th>
</tr>
</thead>
<tbody>
<tr>
<td>401</td>
<td>A-K-(K-(Stp2-C)2)2</td>
<td>1062.7 ± 136.9</td>
<td>0.396 ± 0.06</td>
<td>22.6 ± 1.2</td>
</tr>
<tr>
<td>392</td>
<td>A-K-(K-(Stp2-C)2)2</td>
<td>344.8 ± 88.6</td>
<td>0.267 ± 0.01</td>
<td>24.8 ± 1.3</td>
</tr>
<tr>
<td>402</td>
<td>A-K-(K-(Stp2-C)2)2</td>
<td>367.0 ± 13.0</td>
<td>0.273 ± 0.01</td>
<td>25.2 ± 0.3</td>
</tr>
<tr>
<td>421</td>
<td>A-K-(K-(Stp2-C)2)2</td>
<td>351.6 ± 13.9</td>
<td>0.271 ± 0.02</td>
<td>27.9 ± 1.3</td>
</tr>
<tr>
<td>530</td>
<td>A-K-(K-(Stp2-A)2)2</td>
<td>423.1 ± 102.1</td>
<td>0.371 ± 0.02</td>
<td>14.2 ± 0.4</td>
</tr>
<tr>
<td>531</td>
<td>A-K-(K-(Stp2-A)2)2</td>
<td>410.0 ± 53.6</td>
<td>0.319 ± 0.03</td>
<td>12.1 ± 1.4</td>
</tr>
<tr>
<td>532</td>
<td>A-K-(K-(Stp2-A)2)2</td>
<td>381.6 ± 81.9</td>
<td>0.372 ± 0.04</td>
<td>26.8 ± 0.6</td>
</tr>
<tr>
<td>533</td>
<td>A-K-(K-(Stp2-A)2)2</td>
<td>263.0 ± 31.2</td>
<td>0.280 ± 0.01</td>
<td>25.4 ± 0.6</td>
</tr>
<tr>
<td>492</td>
<td>A-K-(K-(Gtt2-C)2)2</td>
<td>n.d.</td>
<td>-</td>
<td>25.0 ± 0.0</td>
</tr>
<tr>
<td>494</td>
<td>A-K-(K-(Gtt2-C)2)2</td>
<td>496.0 ± 109.8</td>
<td>0.316 ± 0.03</td>
<td>24.9 ± 0.0</td>
</tr>
<tr>
<td>526</td>
<td>A-K-(K-(Gtt2-A)2)2</td>
<td>n.d.</td>
<td>-</td>
<td>10.8 ± 0.6</td>
</tr>
<tr>
<td>527</td>
<td>A-K-(K-(Gtt2-A)2)2</td>
<td>445.3 ± 33.5</td>
<td>0.340 ± 0.02</td>
<td>16.2 ± 0.7</td>
</tr>
<tr>
<td>497</td>
<td>A-K-(K-(Sph2-C)2)2</td>
<td>370.3 ± 65.4</td>
<td>0.310 ± 0.04</td>
<td>28.3 ± 1.0</td>
</tr>
<tr>
<td>519</td>
<td>A-K-(K-(Sph2-C)2)2</td>
<td>258.1 ± 35.1</td>
<td>0.314 ± 0.03</td>
<td>23.2 ± 0.6</td>
</tr>
<tr>
<td>534</td>
<td>A-K-(K-(Sph2-A)2)2</td>
<td>284.4 ± 43.9</td>
<td>0.302 ± 0.02</td>
<td>28.3 ± 1.8</td>
</tr>
<tr>
<td>535</td>
<td>A-K-(K-(Sph2-A)2)2</td>
<td>338.0 ± 54.8</td>
<td>0.275 ± 0.01</td>
<td>19.4 ± 1.8</td>
</tr>
</tbody>
</table>

**Table 1.** Particle size and zeta potential of four-arm oligomers after complexation with pDNA at N/P 12.

### 3.1.7 Four-arm cysteine containing Stp, Gtt and Sph oligomers for siRNA delivery

The synthesized oligomers were also tested in siRNA-mediated gene silencing. The binding of oligomers to siRNA evaluated by gel electrophoresis (Fig. 15 A) shows that cysteine-ended Stp and Sph oligomers have the strongest interaction with siRNA. Gtt analogs hardly bind siRNA, except oligomer 494 at high N/P.

The ethidium bromide exclusion assay (Fig. 15 B) shows that Stp and Sph oligomers have equal siRNA compaction ability, much more efficiently than Gtt oligomers. LinPEI, although it compacts siRNA, shows only weak gene silencing efficiency [160].
Fig. 15. (A) siRNA binding assay of oligomers containing different building blocks. (B) Ethidium bromide exclusion assay.

Gene silencing experiments (Fig. 16; experiments performed by Thomas Fröhlich and Petra Kos, Wagner lab) demonstrate that only cysteine-ended oligomers based on Stp or Sph (but not Gtt) were bioactive. Alanine-ended four-arms did not mediate any gene silencing effect. In contrast to pDNA delivery, Sph oligomers were not beneficial compared with Stp based oligomers.
Fig. 16. Luciferase reporter gene silencing with (A) Stp-, (B) Gtt- and (C) Sph-based oligomers (experiments performed by Thomas Fröhlich and Petra Kos, Wagner lab).
3.1.8 Five-arm Stp oligomers for pDNA and siRNA delivery

As it is known that polymer size is important especially for pDNA delivery, longer Stp oligomers than plain four-branch were synthesized on solid phase by introduction of a Stp tail before branching and terminal cysteines. These oligomers were also evaluated for their properties to bind and deliver pDNA and siRNA.

**Fig. 17 A** shows the results obtained for pDNA binding in the gel shift assay. It is obvious that all compounds can efficiently bind pDNA, as also shown in the ethidium bromide exclusion assay, where 425 has the same cargo compaction ability as the four-arm counterpart 402 (Fig. 17 B). Nevertheless, in the luciferase reporter gene assay the five-arm oligomers did not show any superiority compared to four-arm oligomers (Fig. 17 C, experiment performed by Thomas Fröhlich). As the synthesis is more time consuming, improvement of this class of oligomers was not further pursued.

**Fig. 17.** (A) pDNA binding assay. (B) Ethidium bromide exclusion assay (C) Luciferase assay of cysteine-containing five-arm Stp oligomers and corresponding cell viability data (experiment performed by Thomas Fröhlich, Wagner lab).
Nevertheless, the five-arm oligomers were also tested for their efficiency to bind and deliver siRNA. The siRNA binding assay shows that only the biggest compound 425 can efficiently bind siRNA (Fig. 18 A). Although comparable in compaction efficiency to the four-arm counterpart (Fig. 18 B), efficient gene silencing could only be achieved with 414 (Fig. 18 C, experiment performed by Thomas Fröhlich, Wagner lab).

**Fig. 18.** (A) siRNA binding assay (B) Ethidium bromide exclusion assay. (C) Luciferase gene silencing of cysteine-modified five-arm Stp oligomers (experiment performed by Thomas Fröhlich, Wagner lab).
3.2 Histidine-containing Stp and Gtt oligomers

3.2.1 Introduction

Escaping the cellular endosome before its maturation to lysosomes is a crucial and transfection limiting step before the nucleic acid reaches its site of action. Different strategies have been exploited so as to overcome this obstacle. One possibility is to take advantage of the proton sponge effect, as described for PEI [77]. Therefore, protonable amino groups at an acidic pH of 5-6 are required. Secondary amines within the PEI chain fulfill this demand, but also the amino acid histidine, for instance, with its imidazole side chain (Fig. 19). This residue serves as pH-selective proton sponge, as protonation does not occur before entering the acidic endosome.

Due to this side chain feature, namely facilitation of endosomal escape and thus enhanced payload delivery, various synthetic carriers [161], such as dendrimers [162], cationic polymers [163-165] and lipids [166, 167] have been modified with histidine or imidazole. Therefore, selected Stp and Gtt oligomers were modified with additional histidines and evaluated for the impact on biophysical polyplex properties and nucleic acid transfection. Additionally, as control compounds, four-arm lysine-histidine oligomers based on previous publications by the group around A. J. Mixson [146, 147] were synthesized and compared to Stp and Gtt containing oligomers.

3.2.2 Library design and chemical characterization

Based on results described in section 3.1, cysteine and alanine containing four-arm Stp and Gtt oligomers were further modified with histidines. First, additional histidines were introduced after each coupling of the corresponding building block (Fig. 20 A; ‘lowHis’, bottom left scheme). A higher amount of histidines was synthetically achieved by introduction of the amino acid before coupling the second branching
point and also, additionally, before coupling the terminal cysteine or alanine (Fig. 20 A; 'highHis', bottom right scheme). Alanine was applied as substitute control amino acid for cysteine and histidine, respectively. As additional control sequences, lysine-histidine oligomers based on [146] were synthesized and evaluated (Fig. 20 B).

Fig. 20. (A) Histidine containing four-arm Stp and Gtt oligomers. Histidines were introduced either before building block coupling (lowHis, left scheme) or before the second branching point and before and after each building block (highHis, right scheme). Oligomers were N-terminally modified with cysteines. Alanines were used as control amino acids for both histidine and cysteine. (B) Control sequence based on [146].
Thus, a small library of 18 histidine-containing oligomers and corresponding mutant sequences was generated. All oligomer Ids and accordant sequences with detailed specifications on molecular formula, molecular weight and amount of protonable amines are listed below.

<table>
<thead>
<tr>
<th>Oligomer Id</th>
<th>Sequence</th>
<th>Molecular Formula</th>
<th>Molecular weight [g/mol]</th>
<th>Protonable amines</th>
</tr>
</thead>
<tbody>
<tr>
<td>487</td>
<td>A-K-(K-(H-Stp)3-C)2</td>
<td>C250H449N107O44S4</td>
<td>5786.19</td>
<td>52</td>
</tr>
<tr>
<td>528</td>
<td>A-K-(K-(A-Stp)3-C)2</td>
<td>C214H425N83O44S4</td>
<td>4993.45</td>
<td>40</td>
</tr>
<tr>
<td>490</td>
<td>A-K-(K-((H-Stp)3-A)2)</td>
<td>C250H473N107O44</td>
<td>5682.12</td>
<td>52</td>
</tr>
<tr>
<td>495</td>
<td>A-K-(K-((A-Stp)3-A)2)</td>
<td>C214H425N83O44</td>
<td>4865.19</td>
<td>40</td>
</tr>
<tr>
<td>521</td>
<td>A-K-(K-((H-Gtt)3-C)2)</td>
<td>C233H411N95O45S4</td>
<td>5439.67</td>
<td>40</td>
</tr>
<tr>
<td>524</td>
<td>A-K-(K-((A-Gtt)3-C)2)</td>
<td>C201H387N71O45S4</td>
<td>4646.93</td>
<td>28</td>
</tr>
<tr>
<td>522</td>
<td>A-K-(K-((H-Gtt)3-A)2)</td>
<td>C233H411N95O45</td>
<td>5311.41</td>
<td>40</td>
</tr>
<tr>
<td>525</td>
<td>A-K-(K-((A-Gtt)3-A)2)</td>
<td>C201H387N71O45</td>
<td>4518.67</td>
<td>28</td>
</tr>
<tr>
<td>573</td>
<td>A-K-((H-K-((H-Stp)3-H-C)2)</td>
<td>C285H489N125O51S4</td>
<td>6611.00</td>
<td>58</td>
</tr>
<tr>
<td>575</td>
<td>A-K-((A-Stp)3-A-C)2</td>
<td>C231H453N89O51S4</td>
<td>5421.89</td>
<td>40</td>
</tr>
<tr>
<td>574</td>
<td>A-K-((H-K-((H-Stp)3-H-A)2)</td>
<td>C285H489N125O51</td>
<td>6482.74</td>
<td>58</td>
</tr>
<tr>
<td>576</td>
<td>A-K-((A-Stp)3-A-A)2</td>
<td>C231H453N89O51</td>
<td>5293.63</td>
<td>40</td>
</tr>
<tr>
<td>577</td>
<td>A-K-((H-K-((H-Gtt)3-H-C)2)</td>
<td>C261H429N113O51S4</td>
<td>6094.19</td>
<td>46</td>
</tr>
<tr>
<td>579</td>
<td>A-K-((A-K-((A-Gtt)3-A-C)2)</td>
<td>C203H393N77O51S4</td>
<td>4905.08</td>
<td>28</td>
</tr>
<tr>
<td>578</td>
<td>A-K-((H-K-((H-Gtt)3-H-A)2)</td>
<td>C261H429N113O51</td>
<td>5965.93</td>
<td>46</td>
</tr>
<tr>
<td>580</td>
<td>A-K-((A-K-((A-Gtt)3-A-A)2)</td>
<td>C203H489N177O51</td>
<td>4776.82</td>
<td>28</td>
</tr>
</tbody>
</table>

Table 2. List of histidine-containing oligomers. First eight sequences (shaded light gray) are lowHis oligomers, subsequent eight sequences are highHis oligomers and sequence 582 and 584 (shaded dark grey) are control compounds based on [146].
The purity of the terminal alanine-containing oligomer with the highest molecular weight out of each class (lowHis and highHis) was determined, besides $^1$H-NMR, by RP-HPLC. No significant impurities could be observed (Fig. 21).

![Analytical RP-HPLC traces of histidine-containing oligomers. (A) (H-Stp)$_3$-A, 490 (B) (H-Gtt)$_3$-A, 522 (C) (H-Stp)$_3$-H-A, 574 (D) (H-Gtt)$_3$-H-A, 578.](image)

3.2.3 Biophysical and biological characterization

The effect of histidine introduction on oligomer buffering capacity was determined via acidimetric titrations (experiment performed by Ulrich Lächelt, Wagner lab). The results show the enhanced buffering effect mediated by histidines compared to alanine-containing compounds (Fig. 22), also increasing with the amount of histidines within the oligomers (Fig. 22, left panel vs. right panel). Moreover, the building block Gtt containing two protonable amines shows a higher buffering capacity than Stp with three protonable amines per unit. The results with control oligomer 584 (KHH$_5$) are in the range of His-containing Stp compounds.
Fig. 22. Acidimetric titration of selected histidine-containing oligomers compared to alanine controls (experiment performed by Ulrich Lächelt, Wagner lab).

LowHis oligomers were tested for their pDNA binding ability by gel electrophoresis. This assay revealed that all Stp oligomers apart from compound 490 (with histidines and terminal alanine) bind their cargo efficiently. For the Gtt oligomers, in contrast, histidine containing compounds distinctly exceed the alanine controls (with or without terminal cysteines) in their binding capacity (Fig. 23 A).

The luciferase assay displays the difference in the impact of histidines on Stp and Gtt oligomers (Fig. 23 B, upper panels). Concerning Stp oligomers, histidines were beneficial in case of cysteine-containing compounds, whereas for the terminal alanine modification no improvement could be observed. For Gtt oligomers, histidines increased gene delivery efficiency for both terminal cysteine and alanine modification; for the latter the difference in transfection efficiency at higher N/P ratios was highly significant.
Fig. 23. (A) pDNA binding assay of histidine containing oligomers. Luciferase assay of histidine containing (B) Stp oligomers and Gtt oligomers and corresponding cell viability data below (experiments performed by Petra Kos, Wagner lab).
Furthermore, these compounds were also tested for the ability to mediate gene silencing with siRNA. The capability to bind siRNA was tested by agarose gel electrophoresis and revealed that cysteine containing Stp oligomers, consistent with previous findings, have the best binding abilities due to polyplex stabilization, whereas histidines do not have a positive influence on cargo binding (Fig. 24 A).

However, gene silencing experiments showed that histidines definitely have an impact on siRNA transfection and are beneficial as an additional buffering domain, even leading to a gene silencing effect for Gtt oligomers, although some unspecific toxicity could also be observed (Fig. 24 B).

![Fig. 24. (A) siRNA binding assay. (B) Gene silencing evaluation of histidine containing oligomers (experiments performed by Petra Kos, Wagner lab).](image-url)
Oligomers with a higher amount of histidines (highHis) were also tested for their pDNA binding capacity. **Fig. 25** shows that both cysteine-containing Stp and Gtt oligomers do efficiently bind their cargo. Binding ability declines for histidine-containing oligomers with terminal alanine. Compound 580 ((A-Gtt)$_3$-A-A) cannot retain pDNA at all.

![Fig. 25](image)

*Fig. 25.* pDNA binding assay of highHis oligomers.

Subsequent gene delivery experiments (**Fig. 26**) displayed similar results as obtained with lowHis compounds, showing no significant improvement due to additional histidines.
Results

Fig. 26. Luciferase assay of highHis oligomers and corresponding cell viability data below (experiments performed by Petra Kos, Wagner lab).

Control oligomers 582 (KHH₃) and 584 (KHH₅) both showed in the gel electrophoresis assay efficient pDNA binding (Fig. 27 A). Transfection efficiency, though, did not exceed linPEI level (Fig. 27 B). Therefore, four-arm Stp and Gtt oligomers containing histidines and terminal cysteine remain the most efficient compounds.

Fig. 27. (A) pDNA binding assay of control lysine-histidine oligomers. (B) Luciferase assay and corresponding cell viability data (experiments performed by Petra Kos, Wagner lab).
3.3 Polypropylenimine (PPI) conjugates for pDNA delivery

3.3.1 Introduction

Efficient pDNA delivery with cationic oligomers is known to be dependent also on polymer size. The `gold standard` in terms of transfection linear PEI, for instance, has a molecular weight of 22 kDa and owes its effectiveness also to this feature. High molecular weight, though, is also strongly associated with carrier toxicity [49, 103]. Due to its static structure, accumulation occurs in cells or organs of living systems, causing undesired toxic effects. Low Mw gene vectors, on the other hand, may not provide sufficient polyplex stability in vivo during blood circulation [114, 168, 169]. Therefore, connection of non-toxic small Mw compounds by biodegradable linkages into larger polymeric structures is a possible solution [106, 114, 168, 170-174] for this problem.

In 2008, our lab (Russ and colleagues) presented a method for assembly of better defined structures to so-called `pseudodendrimers` by connecting oligoethylenimine (OEI) units with the biodegradable linker hexanedioldiacrylate (HD) (Fig 28 A), resulting in efficient, high Mw, biocompatible gene carriers [119]. In a subsequent work, the structurally defined dendrimer polypropylenimine (PPI) was used as a core structure and was connected with the same HD linker to either PPI or oligoethylenimine units [135]. Nevertheless, uncertainty of the resulting structure still remained due to its polydisperse nature and absence of precise connection sites.

In 2007 Kim et al. could show that simple PPI surface modification with arginine as additional cationic domain can enhance pDNA transfection efficiency [134].

In order to allow more precise conclusions on structure-activity relationships, this part of the thesis focuses on the generation of more defined biodegradable gene vectors with higher molecular weight and biocompatibility. Therefore, the dendrimer polypropylenimine (PPI) G2 was used again as a core, as it has a defined structure and does not display noteworthy toxicity. Furthermore, its moderate efficiency concerning pDNA transfection leaves room for improvement. Small linear, sequence-defined oligomers consisting of increasing numbers of the building block Stp were used for further modification, as previous experiments in our lab showed that these small oligomers are neither efficient for gene delivery, nor toxic. The aim was to find out whether a combination of these compounds would bring any benefit. Disulfide bonds were chosen as a biodegradable linkage between these compounds, as these
could be generated in a controlled manner and are rather stable in the extracellular environment, not leading to polymer degradation until reaching the reducing cytosolic environment (Fig. 28 B).

![Fig. 28. (A) Pseudodendrimers consisting of HD-linked OEI units (see Russ et al [135]). (B) Defined dendritic structures consisting of PPI G2 core linked via disulfide linkages to sequence-defined Stp oligomers.]

### 3.3.2 Synthetic concept

In order to facilitate reaction of PPI with cysteine-containing linear Stp oligomers, the eight primary amines on the PPI dendrimer surface had to be activated. 3-Nitro-2-pyridinesulfenyl (NPys) modified cysteine (BCNP, Fig. 29 compound 1) was chosen for this purpose, as the NPys acts as both protecting and activating group for the cysteine thiol, thus allowing concerted disulfide bond formation. Therefore, the BCNP carboxylic group was activated with pentafluorophenol (Fig. 29, compound 2), in order to facilitate reaction with the PPI primary amines. After PPI modification to PPI-BCNP (Fig. 29, compound 4), the excess BCNP was removed and the acid-labile boc protecting group was cleaved, leading to PPI-CNP (Fig. 29, compound 5). Subsequently, PPI-CNP was reacted with cysteine containing linear oligomers with 1 - 4 and 5 Stp units. The generated nitropyridine-thione was removed by dialysis (Fig. 29, last reaction step), resulting in compound 6.
Fig. 29. Synthetic concept of PPI conjugates.
First, Boc-Cys(NPys)-OH was activated with pentafluorophenol to BCNP-OPfp 3 and subsequently reacted with PPI G2 to PPI-BCNP 4. After precipitation for excess BCNP-OPfp removal, PPI-BCNP 4 was deprotected, resulting in PPI-CNP 5. PPI-CNP was subsequently reacted with linear, cysteine-containing Stp oligomers and purified by dialysis to yield compound 6 (n = 1-3, 5).
3.3.3 Chemical characterization

Identity of synthesized intermediates 4 and 5 was confirmed by $^1$H-NMR. **Fig. 30** shows the spectra of PPI after reaction with BCNP (A) and after cleavage of the boc protection group (B). Integration confirmed full modification of the PPI core with BCNP.

![Fig. 30. $^1$H-NMR spectra of (A) PPI-BCNP 4 in MeOH-D$_4$ and (B) PPI-CNP 5 in D$_2$O.](image)

In order to allow concerted and precise modification of the activated PPI, purity of the PPI-CNP core compound had to be ensured. This was confirmed by analytical RP-HPLC (**Fig. 31**). The analytical run was monitored at two wavelengths: 220 nm (**Fig. 31**, red chromatogram) for amide bond and 340 nm (black chromatogram) for NPys detection. The overlay shows that NPys can only be found in the highly pure product peak.

![Fig. 31. Analytical RP-HPLC trace of purified PPI-CNP 5 performed on a C$_{18}$ column and monitored at 220 nm (red chromatogram) and 340 nm (black chromatogram).](image)
Linear Stp oligomers with increasing chain length (n= 1-3, 5) were generated by SPPS and product identity was confirmed by ¹H-NMR. Subsequently, reaction progress of PPI-CNP with linear Stp oligomers was monitored \textit{in situ} by spectrophotometric quantification of the released nitropyridine-thione. After dialysis and lyophilization of the products 6 with n=1-3, 5 (see Figure 33 A), completion of reaction could be confirmed by lack of NPys protons in the ¹H-NMR spectrum (Fig. 32). Successful synthesis of the desired compound was further confirmed by additional quantification of generated disulfide bonds by the TCEP assay and lack of free thiols (Ellman`s assay).

![Exemplary ¹H-NMR spectrum of compound 6, n=2, obtained by reaction of PPI-CNP 5 with C-Stp2.](image)

3.3.4 Biophysical and biological characterization

Dynamic light scattering measurements show that all PPI-(C-C-Stpₙ)₆/pDNA polyplexes are approximately 200 – 400 nm in size. Attempted particle formation of pDNA with PPI G2 displayed only aggregates with a size of > 1 µm. Surface charge of all polyplexes was above +20 mV (Fig. 33 A).

The binding efficiency of the PPI conjugates to pDNA was determined by gel electrophoresis. Only PPI G2 and compound 536 with 5 Stp/chain were able to fully bind pDNA at all N/P. Concerning the smaller conjugates, the longer the Stp chain, the higher also the binding affinity (Fig. 33 B).
PPI conjugates were evaluated for their gene delivery efficiency and cytotoxicity on Neuro2A cells. Consistent with the biophysical characterization results, in the luciferase assay compound 418 with 1 Stp/chain showed the lowest efficiency compared to PPI G2 alone and control linPEI. Best results in terms of transfection efficiency could be achieved with conjugates containing 3 and 5 Stp/chain, whereas the longest chain did not bring any significant benefit. All compounds did not affect the cell metabolic activity, thus displaying high biocompatibility (Fig. 34, experiments performed by Petra Kos).
Fig. 34. Luciferase assay of transfections with PPI-C-(C-Stp₈)₈ polymer 6/pDNA complexes and corresponding cell viability data (experiments performed by Petra Kos).
4 DISCUSSION

Nucleic acid delivery with cationic polymers is often hindered by low efficiency and toxicity. Among others, cationic polymers like polyethylenimine have the ability to reversibly compact pDNA through electrostatic interaction into stable polyplexes. Thus, the payload can reach undamaged the target cell compartment, namely the nucleus, where it can fulfil its task.

Such polymers, although showing promising results in terms of transfection efficiency and cytotoxicity, are still accompanied by a crucial drawback which hampers essential structure-activity relationship studies: polydispersity.

The concept of solid-phase supported synthesis (SPS) shows a way out of this dilemma. This method allows step-by-step polymer chain elongation and therefore exact position control of the inserted compound. Beyond linear compounds, introduction of lysines with two primary amines each facilitates the synthesis of branched oligomers and easy increase of molecular weight by parallel arm elongation. Thus, generation of precise, sequence-defined oligomers is possible, allowing conclusions on structure-activity relationships.

4.1 Four- and five-arm oligo(ethanamino)amides for pDNA and siRNA delivery

As already mentioned, solid-phase supported synthesis can facilitate fast assembly of sequence-defined cationic oligomers [153, 175-177] with exact control on the position of introduced modifications. Using artificial amino acids which contain the 1,2-diaminoethane motif [154], this strategy was applied for assembling carriers for pDNA and siRNA [155, 159]. In the first chapter of this thesis, a small library of branched, four-arm oligomers was described. Two simple, straightforward modifications converted moderately active pDNA transfection carriers, four-arm Stp3 (288) or Stp4 (289) [155] into 1000-fold more potent pDNA transfection agents, Sph3-C (497) and Sph4-C (519).

The first successful modification was the incorporation of cysteines at the N-terminal end of the four arms. Disulfide bonds, either directly incorporated into transfection carriers or, as in the current study, formed after nucleic acid complexation, can be very beneficial [174, 178-180], both for complex stability in the extracellular space,
and for biocompatibility due to cleavage of the carrier into low-molecular fragments in the reducing intracellular environment [109]. Consistently, the cysteine-ended oligomers displayed pDNA and siRNA transfection activity without significant cytotoxicity. Polyplex dissociation assays of Stp and Sph polyplexes confirmed the importance of cysteine stabilization, whereas stronger binding of the oligomers containing 4 building blocks/arm did not improve transfection significantly. This result shows that a higher binding and compaction ability is not necessarily beneficial, as it may hamper cargo release in the cytosol.

In order to further increase molecular weight, a Stp tail was added before introduction of the lysine branching points in four-arm oligomers, thus creating cysteine-terminated five-arm Stp compounds. Stp tails and arms correlated in length, thus containing 2, 3 and four Stp units. Biophysical and biological evaluation of these compounds, though, did not reveal any benefit compared to their four-arm counterparts. This finding further emphasizes the importance of the optimal structure for maximal activity.

The second optimization resulted from defined variation of the artificial oligoamino acid building block, differing in the repeats of 1,2-diaminoethane units. This motif [78, 83] is responsible for the high transfection activity of PEI [13, 76, 77, 174, 181] and related polymers [81, 82, 155, 180, 182], due to unique dynamic properties, reversibly changing the cationic character by endosomal protonation and mediating endosomal escape. Within the polyamide chains of the four-arm oligomers, each building block Gtt, Stp and Sph provides two terminal amide nitrogens and two, three, or four protonable secondary amine nitrogens per unit. For both pDNA compaction and transfection activity, the building blocks ranked in the very clear order of Sph>Stp>>Gtt. Interestingly, extending the chain lengths beyond 3 building blocks per arm had marginal impact on the performance. Stp5-C (421, with 64 protonatable nitrogens) has a far lower efficiency than Sph3-C (497, 52 protonatable nitrogens) and Sph4-C (519, 68 protonatable nitrogens). For the much smaller siRNA cargo, Sph and Stp however displayed very similar binding activity, with Stp providing best gene silencing efficiency. Cysteine mediated stabilization by disulfide formation was strictly required for siRNA delivery. In conclusion, compaction ability (especially in case of pDNA) and polyplex stabilization (especially for siRNA) are major delivery requirements. Defined carriers generated by solid-phase supported synthesis can
accomplish this effectively, also providing insight into structure-activity relationships and manifold possibilities for further improvement.

4.2 Histidine-containing Stp and Gtt oligomers

The amino acid histidine has due to its imidazole side chain the property for selective protonation at acidic pH. This feature is crucial for one of the main bottlenecks within nucleic acid delivery with cationic carriers – endosomal escape. Therefore, this additional proton sponge was already used for enhancing the transfection efficiency of various gene carriers [161].

As SPS allows selective introduction of activity-enhancing moieties, histidines were inserted in an alternating manner into four-arm oligomers with three Stp or Gtt/arm and terminal cysteine. Thus, compounds with a low amount (‘lowHis’) and with a higher amount (‘highHis’) of histidines were generated. By replacing histidine and/or the terminal cysteine with alanine as a control amino acid, direct conclusions on structure-activity relationships could be drawn.

By these means, a library of sixteen histidine-containing oligomers and alanine counterparts was generated. Identity and purity was confirmed by $^1$H-NMR and RP-HPLC. Acidimetric titrations (experiment performed by Ulrich Lächelt, Wagner lab) confirmed the higher buffering capacity at acidic pH mediated by histidines compared to alanine-containing mutants. Also, Gtt oligomers with two protonable amines per unit showed a higher buffering capacity than Stp oligomers with three protonable amines per unit.

In the gel electrophoresis assay, the ‘histidine effect’ had the highest impact on Gtt oligomers. LowHis and highHis Gtt oligomers with terminal cysteines (521, 577) equalized the Stp counterparts (487, 573) in terms of pDNA binding. Consistently, in the luciferase assay all these compounds showed similar transfection efficiency, exceeding linPEI levels and showing no cytotoxic effects. Moreover, cysteine-terminated oligomers were, consistent with previous findings, more efficient than the alanine mutants due to polyplex stabilization, whereas replacement of histidine with alanine had a greater impact for the Gtt oligomers, leading to clearly lower transfection rates.

Nevertheless, significant improvement in terms of transfection efficiency due to introduction of additional histidines (lowHis vs. highHis oligomers) could not be observed.
The impact of histidine-introduction could also be observed in gene silencing experiments. SiRNA transfection with cysteine-containing lowHis oligomers revealed that introduction of histidines considerably improved gene silencing compared to alanine mutants. Even for Gtt oligomers a silencing effect could be shown, even though unspecific toxicity could also be observed.

Also, the new histidine-containing Stp and Gtt oligomers were compared with histidine-rich structures (582, 584) based on the work of A. J. Mixson [146]. These control oligomers showed transfection efficiency similar to linPEI but could not reach luciferase expression levels mediated by the best Stp and Gtt compounds.

### 4.3 Polypropylenimine (PPI) conjugates for pDNA delivery

The `gold standard` in terms of gene delivery, namely PEI, owes its efficiency also to its high molecular weight of 22 kDa but is polydispers by nature [76]. As high molecular weight of cationic polymers, though, is associated on the one hand with better transfection efficiency but on the other hand also with cytotoxicity [49], gene carriers with the feature of environment-triggered cargo release have the potential to overcome this drawback. Therefore, in order to increase molecular weight while maintaining a defined structure, the synthetic concept implied coupling the symmetrical polypropylenimine dendrimer [126] to linear, sequence-defined Stp oligomers. Biodegradability was achieved by modification of the eight primary amines on the PPI surface with activated cysteines, making them feasible for reaction with free thiols. Linear oligomers consisting of increasing amount of the cationic building block Stp (1-3 and 5 units) and containing a terminal cysteine with a free thiol were coupled to this activated core, so as to create reducible disulfide linkages. Thus, four compounds with increasing molecular weight were assembled (418 Stp1, 427 Stp2, 428 Stp3, 536 Stp5) and compared to unmodified generation 2 (G2) PPI. The successful reaction was confirmed by chemical characterization methods.

Biophysical evaluation of these compounds by the pDNA binding assay revealed that the binding affinity increases with oligomer chain length, whereas only the compound with the highest Mw (536 Stp5) could efficiently bind pDNA. PPI alone is also very efficient in terms of pDNA binding.

Biological testing for pDNA transfection efficiency by the luciferase assay showed that the oligomers containing the shortest Stp chain were even less effective than PPI.
alone; results consistent with the findings in the gel shift assay. PPI coupled to oligomers with 3 and 5 Stp/chain \((428, 536)\) were the most efficient for pDNA delivery, whereas \(536\) (Stp5) did not show any significant improvement compared to \(428\) (Stp3), which correlates also with the results obtained with four-arm oligomers. Size and zeta potential measurements also offered an explanation for the transfection efficiency of PPI alone – very large particle size (> 1µm) and aggregates facilitate cellular uptake.

Nevertheless, transfection efficiency of the best conjugates is in the range of PEI, thus encouraging further efforts for optimization. Furthermore, the synthetic concept of PPI primary amine activation offers a platform for novel conjugates.
5 CONCLUSION AND OUTLOOK

Solid-phase supported synthesis (SPS) and subsequent biological evaluation of branched, sequence-defined oligomers displayed their potential as efficient nucleic acid carriers. Optimized synthesis of plain four-arm oligomers consisting of the cationic building block Stp has paved the way for further carrier optimization. Significant enhancement of pDNA and, even more, of siRNA transfection efficiency was achieved by simple N-terminal cysteine introduction due to resulting enhanced polyplex stabilization. Additionally, the protonable amine density within the used building block (Gtt, Stp, Sph) has proven to also a very important feature, with Sph showing the highest efficiency; a finding which can be exploited for further structure variations. Finally, SPS facilitated introduction of histidines within four-arm oligomers, increasing pH-specific oligomer buffering capacity and thus transfection efficiency. Thus, the four-arm oligomers described in this work may be the first steps towards highly efficient and biocompatible nucleic acid carriers. Due to the synthetic method used, namely solid phase supported synthesis, there are still manifold possibilities for improvement and optimization.

Furthermore, the synthetic pathway established for generation of PPI conjugates offers a platform for further development, as the activated dendritic core can be modified with further adequate moieties. Moreover, this method can be used for modification of other core structures with primary amines on the surface.

In conclusion, branched cationic oligomers generated by means of SPS offer a broad platform as efficient and biocompatible nucleic acid carriers. Due to controlled sequence assembly, conclusions on structure-activity relationships are possible – a crucial starting point for further development of even more effective non-viral vectors. Furthermore, the possibility of fast combinatorial synthesis offered by SPS and feasible purification and analytical methods offer manifold possibilities for the development of novel and potent structures.
6  SUMMARY

Synthetic nucleic acid carrier systems got more and more into focus during the last decades as they offer the opportunity to overcome drawbacks associated with viral vectors. Over the years, linear polyethylenimine (linPEI) has established itself as the `gold standard` in terms of nucleic acid transfection efficiency. Various modifications have even increased its effectiveness and reduced toxicity, but polydispersity hampered precise conclusions on structure-activity relationships.

Solid-phase supported synthesis shows a way out of this dilemma, as it offers the possibility for sequence-controlled assembly of cationic oligomers and also the option for directed sequential modifications.

The aim of this thesis was the synthesis and optimization of branched, sequence-defined and biocompatible oligomers via SPS for generation of highly efficient nucleic acid carriers. First, four-branched oligomers consisting of lysines as branching points and the artificial amino acid Stp were synthesized with an increasing number of Stp per arm. Chemical characterization confirmed identity and purity of the compounds; biophysical and biological evaluation showed promising results in terms of pDNA transfection.

Therefore, the most potent structures were further modified with terminal cysteines for polyplex stabilization, which led to significant improvement in terms of pDNA transfection and also of gene silencing with siRNA. These results were undermined by gel electrophoresis assays in so far, that cysteines play a crucial role concerning polyplex stabilization. Additionally, further artificial oligoamino acids besides Stp with three protonable amines per unit were evaluated, namely Gtt with two and Sph with four protonable amines, respectively. The differing repeats of the 1,2-diaminoethane units also resulted in differing impact on pDNA delivery, ranking in the order Sph>Stp>>Gtt. In terms of siRNA-mediated gene silencing, Sph and Stp showed similar results, whereas Gtt-containing oligomers did not show any effect. Hence, it could be concluded that optimal oligomer/siRNA polyplex stabilization due to electrostatic interactions and disulfide formation is required for efficient gene silencing.

Another successful modification of Stp and Gtt oligomers was the introduction of the amino acid histidine. Selective protonation of its imidazole side chain at acidic pH
enhances endosomal escape, a crucial bottleneck in the nucleic acid delivery pathway. Histidine-containing oligomers were more efficient concerning pDNA and siRNA delivery than the alanine-containing control structures, undermining the importance of endosomal escape for successful transfection.

A further aim of this thesis was to generate defined, non-toxic structures with a higher Mw consisting of low Mw subunits coupled with biodegradable linkages. The structurally defined dendrimer polypropylenimine (PPI) was chosen as a core and its primary amines on the surface were modified in so far as to react with free thiols to reducible disulfide bonds. By these means, sequence-defined, linear Stp oligomers with increasing Stp units per chain were coupled to the activated PPI core and evaluated for pDNA delivery. The resulting non-toxic compounds showed correlation between increasing Stp chain length and transfection efficiency.
# 7 APPENDIX

## 7.1 List of used compounds

### 7.1.1 Four- and five-arm oligomers

<table>
<thead>
<tr>
<th>Oligomer Id</th>
<th>Sequence</th>
<th>Molecular Formula</th>
<th>Molecular weight [g/mol]</th>
<th>Protonable amines</th>
</tr>
</thead>
<tbody>
<tr>
<td>286</td>
<td>A-K-(K-(Stp)(_2))(_2)</td>
<td>C(<em>{189})H(</em>{423})N(<em>{27})O(</em>{13})</td>
<td>1559.05</td>
<td>16</td>
</tr>
<tr>
<td>287</td>
<td>A-K-(K-(Stp)(_2))(_2)</td>
<td>C(<em>{113})H(</em>{243})N(<em>{47})O(</em>{21})</td>
<td>2644.48</td>
<td>28</td>
</tr>
<tr>
<td>288</td>
<td>A-K-(K-(Stp)(_3))(_2)</td>
<td>C(<em>{168})H(</em>{443})N(<em>{67})O(</em>{29})</td>
<td>3729.92</td>
<td>40</td>
</tr>
<tr>
<td>289</td>
<td>A-K-(K-(Stp)(_4))(_2)</td>
<td>C(<em>{213})H(</em>{443})N(<em>{87})O(</em>{37})</td>
<td>4815.36</td>
<td>52</td>
</tr>
<tr>
<td>392</td>
<td>A-K-(K-(Stp)(_3))(_2)</td>
<td>C(<em>{173})H(</em>{463})N(<em>{71})O(</em>{33})S(_{4})</td>
<td>4142.49</td>
<td>40</td>
</tr>
<tr>
<td>401</td>
<td>A-K-(K-(Stp)(_2))(_2)</td>
<td>C(<em>{129})H(</em>{263})N(<em>{51})O(</em>{25})S(_{4})</td>
<td>3057.05</td>
<td>28</td>
</tr>
<tr>
<td>402</td>
<td>A-K-(K-(Stp)(_3))(_2)</td>
<td>C(<em>{225})H(</em>{463})N(<em>{91})O(</em>{41})S(_{4})</td>
<td>5227.93</td>
<td>52</td>
</tr>
<tr>
<td>421</td>
<td>A-K-(K-(Stp)(_5))(_2)</td>
<td>C(<em>{273})H(</em>{663})N(<em>{111})O(</em>{49})S(_{4})</td>
<td>6313.37</td>
<td>64</td>
</tr>
<tr>
<td>530</td>
<td>A-K-(K-(Stp)(_2))(_2)</td>
<td>C(<em>{129})H(</em>{263})N(<em>{51})O(</em>{25})S(_{4})</td>
<td>2928.80</td>
<td>28</td>
</tr>
<tr>
<td>531</td>
<td>A-K-(K-(Stp)(_3))(_2)</td>
<td>C(<em>{173})H(</em>{463})N(<em>{71})O(</em>{33})S(_{4})</td>
<td>4014.23</td>
<td>40</td>
</tr>
<tr>
<td>532</td>
<td>A-K-(K-(Stp)(_4))(_2)</td>
<td>C(<em>{225})H(</em>{463})N(<em>{91})O(</em>{41})S(_{4})</td>
<td>5099.67</td>
<td>52</td>
</tr>
<tr>
<td>533</td>
<td>A-K-(K-(Stp)(_5))(_2)</td>
<td>C(<em>{273})H(</em>{663})N(<em>{111})O(</em>{49})S(_{4})</td>
<td>6185.11</td>
<td>64</td>
</tr>
<tr>
<td>414</td>
<td>A-Stp(_2)-K-(K-(Stp)(_2))(_2)</td>
<td>C(<em>{153})H(</em>{313})N(<em>{61})O(</em>{59})S(_{4})</td>
<td>3599.77</td>
<td>34</td>
</tr>
<tr>
<td>424</td>
<td>A-Stp(_3)-K-(K-(Stp)(_3))(_2)</td>
<td>C(<em>{213})H(</em>{447})N(<em>{86})O(</em>{36})S(_{4})</td>
<td>4949.64</td>
<td>49</td>
</tr>
<tr>
<td>425</td>
<td>A-Stp(_4)-K-(K-(Stp)(_4))(_2)</td>
<td>C(<em>{273})H(</em>{663})N(<em>{111})O(</em>{49})S(_{4})</td>
<td>6313.37</td>
<td>64</td>
</tr>
<tr>
<td>492</td>
<td>A-K-(K-(Gtt)(_3))(_2)</td>
<td>C(<em>{165})H(</em>{427})N(<em>{59})O(</em>{33})S(_{4})</td>
<td>3794.00</td>
<td>28</td>
</tr>
<tr>
<td>494</td>
<td>A-K-(K-(Gtt)(_4))(_2)</td>
<td>C(<em>{209})H(</em>{415})N(<em>{75})O(</em>{41})S(_{4})</td>
<td>4763.27</td>
<td>36</td>
</tr>
<tr>
<td>526</td>
<td>A-K-(K-(Gtt)(_3))(_2)</td>
<td>C(<em>{165})H(</em>{427})N(<em>{59})O(</em>{33})S(_{4})</td>
<td>3665.74</td>
<td>28</td>
</tr>
<tr>
<td>527</td>
<td>A-K-(K-(Gtt)(_4))(_2)</td>
<td>C(<em>{209})H(</em>{415})N(<em>{75})O(</em>{41})S(_{4})</td>
<td>4635.01</td>
<td>36</td>
</tr>
<tr>
<td>497</td>
<td>A-K-(K-(Sph)(_3))(_2)</td>
<td>C(<em>{201})H(</em>{423})N(<em>{83})O(</em>{33})S(_{4})</td>
<td>4659.31</td>
<td>52</td>
</tr>
<tr>
<td>519</td>
<td>A-K-(K-(Sph)(_2))(_2)</td>
<td>C(<em>{249})H(</em>{623})N(<em>{105})O(</em>{41})S(_{4})</td>
<td>5744.74</td>
<td>68</td>
</tr>
<tr>
<td>534</td>
<td>A-K-(K-(Sph)(_3))(_2)</td>
<td>C(<em>{201})H(</em>{423})N(<em>{83})O(</em>{33})S(_{4})</td>
<td>4531.05</td>
<td>52</td>
</tr>
<tr>
<td>535</td>
<td>A-K-(K-(Sph)(_4))(_2)</td>
<td>C(<em>{249})H(</em>{623})N(<em>{105})O(</em>{41})S(_{4})</td>
<td>5616.48</td>
<td>68</td>
</tr>
<tr>
<td>487</td>
<td>A-K-(K-(H-Stop)(_3))(_2)</td>
<td>C(<em>{250})H(</em>{449})N(<em>{107})O(</em>{44})S(_{4})</td>
<td>5786.19</td>
<td>52</td>
</tr>
<tr>
<td>528</td>
<td>A-K-(K-(1-Ar)(_3))(_2)</td>
<td>C(<em>{214})H(</em>{423})N(<em>{83})O(</em>{44})S(_{4})</td>
<td>4993.45</td>
<td>40</td>
</tr>
<tr>
<td>490</td>
<td>A-K-(K-(H-Stop)(_3))(_2)</td>
<td>C(<em>{250})H(</em>{473})N(<em>{107})O(</em>{44})S(_{4})</td>
<td>5682.12</td>
<td>52</td>
</tr>
</tbody>
</table>
7.1.2 Linear cysteine-containing Stp oligomers

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Molecular Formula</th>
<th>Molecular weight [g/mol]</th>
<th>Protonable amines</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-Stp</td>
<td>C_{15}H_{32}N_{4}O_{4}S</td>
<td>392.52</td>
<td>4</td>
</tr>
<tr>
<td>C-Stp₂</td>
<td>C_{27}H_{53}N₁O₂S</td>
<td>659.84</td>
<td>7</td>
</tr>
<tr>
<td>C-Stp₃</td>
<td>C_{39}H_{70}N₁O₂S</td>
<td>931.20</td>
<td>10</td>
</tr>
<tr>
<td>C-Stp₄</td>
<td>C_{51}H_{103}N₂O₁S</td>
<td>1202.56</td>
<td>13</td>
</tr>
<tr>
<td>C-Stp₅</td>
<td>C_{63}H_{136}N₂O₁₂S</td>
<td>1473.92</td>
<td>16</td>
</tr>
</tbody>
</table>

7.1.3 PPI conjugates

<table>
<thead>
<tr>
<th>Conjugate Id</th>
<th>Sequence</th>
<th>Molecular Formula</th>
<th>Molecular weight [g/mol]</th>
<th>Protonable amines</th>
</tr>
</thead>
<tbody>
<tr>
<td>418</td>
<td>PPI-(C-C-Stp)₈</td>
<td>C_{268}H_{556}N_{76}O_{24}S_{16}</td>
<td>4718.51</td>
<td>46</td>
</tr>
<tr>
<td>427</td>
<td>PPI-(C-C-Stp₂)₈</td>
<td>C_{280}H_{576}N_{110}O_{56}S_{16}</td>
<td>6893.31</td>
<td>70</td>
</tr>
<tr>
<td>428</td>
<td>PPI-(C-C-Stp₃)₈</td>
<td>C_{376}H_{776}N_{150}O_{72}S_{16}</td>
<td>9064.19</td>
<td>94</td>
</tr>
<tr>
<td>430</td>
<td>PPI-(C-C-Stp₄)₈</td>
<td>C_{472}H_{976}N_{190}O_{88}S_{16}</td>
<td>11227.33</td>
<td>118</td>
</tr>
<tr>
<td>536</td>
<td>PPI-(C-C-Stp₅)₈</td>
<td>C_{568}H_{1176}N_{230}O_{104}S_{16}</td>
<td>13405.93</td>
<td>150</td>
</tr>
</tbody>
</table>
7.2 Analytical Data

1H-NMR chemical shifts of the synthesized compounds (all measured at 400 MHz in D2O). Compound mass was not determined unless otherwise stated.

7.2.1 Four- and five-arm oligomers

Oligomer Id: 286  
Sequence: A-K-(K-(Stp)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 16 H, -CH2- Tp), 3.48-3.54 (m, 48 H, -CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids).

Calculated Mass: 1560.05 [M+H]+
Mass found: 1558.823 [M+H]+

Oligomer Id: 287  
Sequence: A-K-(K-(Stp)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 32 H, -CO-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 32 H, -CH2- Tp), 3.48-3.54 (m, 96 H, -CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids).

Calculated Mass: 2645.48 [M+H]+
Mass found: 2646.258 [M+H]+

Oligomer Id: 288  
Sequence: A-K-(K-(Stp)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids).

Calculated Mass: 3730.92 [M+H]+
Mass found: 3729.070 [M+H]+

Oligomer Id: 289  
Sequence: A-K-(K-(Stp)4)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH2- Tp), 3.48-3.54 (m, 192 H, -CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids).
Calculated Mass: 4186.36 [M+H]^+
Mass found: 4187.455 [M+H]^+

Oligomer Id: 403
Sequence: A-K-(K-(Stp3)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 80 H, -CO-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH2- Tp), 3.48-3.54 (m, 240 H, -CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids).

Oligomer Id: 401
Sequence: A-K-(K-(Stp2-C)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 32 H, -CO-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 32 H, -CH2- Tp), 3.48-3.54 (m, 96 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 392
Sequence: A-K-(K-(Stp3-C)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 402
Sequence: A-K-(K-(Stp4-C)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH2- Tp), 3.48-3.54 (m, 192 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 421
Sequence: A-K-(K-(Stp5-C)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 80 H, -CO-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH2- Tp), 3.48-3.54 (m, 240 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 530
Sequence: A-K-(K-(Stp2-A)2)2
δ (ppm) = 1.3-1.8 (m, 33 H, γδε lysine, -CH3 alanine), 2.5-2.6 (m, 32 H, -CO-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 32 H, -CH2- Tp), 3.48-3.54 (m, 96 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids).
Oligomer Id: 531
Sequence: A-K-(K-(Stp\textsubscript{3}-A)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 33 H, γδε lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 144 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 532
Sequence: A-K-(K-(Stp\textsubscript{4}-A)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 33 H, γδε lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 64 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 192 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 533
Sequence: A-K-(K-(Stp\textsubscript{5}-A)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 33 H, γδε lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 80 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 240 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 414
Sequence: A-Stp\textsubscript{2}-K-(K-(Stp\textsubscript{2}-C)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 40 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 40 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 120 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 424
Sequence: A-Stp\textsubscript{3}-K-(K-(Stp\textsubscript{3}-C)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 60 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 60 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 180 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 425
Sequence: A-Stp\textsubscript{4}-K-(K-(Stp\textsubscript{4}-C)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 80 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 240 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 492
Sequence: A-K-(K-(Gtt\textsubscript{3}-C)\textsubscript{2})\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 21 H, γδε lysine, -CH\textsubscript{3} alanine), 2.2-2.3 (t, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 1.8-1.9 (m, 24 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.0 (m, 8 H, βH cysteine),
3.1 (t, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH₂- Tt), 3.4-3.5 (m, 96 H, -CH₂- Tt), 4.1-4.3 (m, 8 H, αH amino acids).

**Oligomer Id: 494**

Sequence: A-K-(K-(Gtt₄-C)₂)

δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH₃ alanine), 2.2-2.3 (t, 64 H, -CO-CH₂-CH₂-CO-), 1.8-1.9 (m, 32 H, -CO-CH₂-CH₂-CH₂-CH₂-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.3 (m, 64 H, -CH₂- Tt), 3.4-3.5 (m, 128 H, -CH₂- Tt), 4.1-4.3 (m, 8 H, αH amino acids).

**Oligomer Id: 497**

Sequence: A-K-(K-(Sph₃-C)₂)

δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH₃ alanine), 2.5-2.6 (m, 48 H, -CO-CH₂-CH₂-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH₂- Tp), 3.4-3.6 (m, 192 H, -CH₂- Tp), 4.1-4.3 (m, 8 H, αH amino acids).

**Oligomer Id: 519**

Sequence: A-K-(K-(Sph₄-C)₂)

δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH₃ alanine), 2.5-2.6 (m, 64 H, -CO-CH₂-CH₂-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH₂- Tp), 3.4-3.6 (m, 256 H, -CH₂- Tp), 4.1-4.3 (m, 8 H, αH amino acids).
Oligomer Id: 534

Sequence: A-K-(K-(Sph\textsubscript{3}-A))\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH\textsubscript{2}-Tp), 3.4-3.6 (m, 192 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 535

Sequence: A-K-(K-(Sph\textsubscript{4}-A))\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 64 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH\textsubscript{2}-Tp), 3.4-3.6 (m, 256 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH amino acids).

Oligomer Id: 487

Sequence: A-K-(K-((H-Stp)\textsubscript{3}-C))\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.4 (m, 48 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 144 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH lysine, alanine, cysteine), 4.7 (m, 12 H, αH histidine), 7.3 (12 H, imidazole H histidine), 8.6 (12 H, imidazole H histidine).

Oligomer Id: 528

Sequence: A-K-(K-((A-Stp)\textsubscript{3}-C))\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 57 H, γδεH lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 144 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 20 H, αH amino acids).

Oligomer Id: 490

Sequence: A-K-(K-((H-Stp)\textsubscript{3}-A))\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.4 (m, 48 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 144 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 8 H, αH lysine, alanine), 4.7 (m, 12 H, αH histidine), 7.3 (12 H, imidazole H histidine), 8.6 (12 H, imidazole H histidine).

Oligomer Id: 495

Sequence: A-K-(K-((A-Stp)\textsubscript{3}-A))\textsubscript{2}

δ (ppm) = 1.3-1.8 (m, 69 H, γδεH lysine, -CH\textsubscript{3} alanine), 2.5-2.6 (m, 48 H, -CO-CH\textsubscript{2}-CH\textsubscript{2}-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH\textsubscript{2}-Tp), 3.48-3.54 (m, 144 H, -CH\textsubscript{2}-Tp), 4.1-4.3 (m, 20 H, αH amino acids).
Oligomer Id: 521
Sequence: A-K-(K-((H-Gtt)3-C)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.3 (m, 48 H, -CH2-Tt), 3.4-3.5 (m, 96 H, -CH2-Tt), 4.1-4.3 (m, 8 H, αH lysine, alanine, cysteine), 4.7 (m, 12 H, αH histidine) 7.3 (12 H, imidazole H histidine), 8.6 (12 H, imidazole H histidine).

Oligomer Id: 524
Sequence: A-K-(K-((A-Gtt)3-C)2)2
δ (ppm) = 1.3-1.8 (m, 57 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH2-Tt), 3.4-3.5 (m, 96 H, -CH2-Tt), 4.1-4.3 (m, 20 H, αH amino acids).

Oligomer Id: 522
Sequence: A-K-(K-((H-Gtt)3-A)2)2
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.3 (m, 48 H, -CH2-Tt), 3.4-3.5 (m, 96 H, -CH2-Tt), 4.1-4.3 (m, 8 H, αH lysine, alanine), 4.7 (m, 12 H, αH histidine) 7.3 (12 H, imidazole H histidine), 8.6 (12 H, imidazole H histidine).

Oligomer Id: 525
Sequence: A-K-(K-((A-Gtt)3-A)2)2
δ (ppm) = 1.3-1.8 (m, 69 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH2-Tt), 3.4-3.5 (m, 96 H, -CH2-Tt), 4.1-4.3 (m, 20 H, αH amino acids).

Oligomer Id: 525
Sequence: A-K-(K-((H-Stp)3-H-C)2)2
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 36 H, βH lysine, histidine), 3.2-3.4 (m, 48 H, -CH2-Tp), 3.48-3.54 (m, 144 H, -CH2-Tp), 4.1-4.3 (m, 8 H, αH lysine, alanine, cysteine), 4.7 (m, 14 H, αH histidine) 7.3 (14 H, imidazole H histidine), 8.6 (14 H, imidazole H histidine).
Oligomer Id: 575  
δ (ppm) = 1.3-1.8 (m, 75 H, γδε H lysine, -CH₃ alanine), 2.5-2.6 (m, 48 H, -CO-CH₂-CH₂-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH₂-TP), 3.48-3.54 (m, 144 H, -CH₂-TP), 4.1-4.3 (m, 26 H, αH amino acids).

Oligomer Id: 574  
Sequence: A-K-(H-K-((H-Stp)_3-H-A)_2)_2  
δ (ppm) = 1.3-1.8 (m, 33 H, γδε H lysine, -CH₃ alanine), 2.5-2.6 (m, 48 H, -CO-CH₂-CH₂-CO-), 3.1-3.2 (m, 36 H, βH lysine, histidine), 3.2-3.4 (m, 48 H, -CH₂-TP), 3.48-3.54 (m, 144 H, -CH₂-TP), 4.1-4.3 (m, 8 H, αH lysine, alanine), 4.7 (m, 14 H, αH histidine) 7.3 (14 H, imidazole H histidine), 8.6 (14 H, imidazole H histidine).

Oligomer Id: 576  
δ (ppm) = 1.3-1.8 (m, 87 H, γδε H lysine, -CH₃ alanine), 2.5-2.6 (m, 48 H, -CO-CH₂-CH₂-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH₂-TP), 3.48-3.54 (m, 144 H, -CH₂-TP), 4.1-4.3 (m, 26 H, αH amino acids).

Oligomer Id: 577  
Sequence: A-K-(H-K-((H-Gtt)_3-H-C)_2)_2  
δ (ppm) = 1.3-1.8 (m, 21 H, γδε H lysine, -CH₃ alanine), 2.2-2.3 (t, 48 H, -CO-CH₂-CH₂-CH₂-CO-), 1.8-1.9 (m, 24 H, -CO-CH₂-CH₂-CH₂-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 42 H, βH lysine, histidine), 3.2-3.3 (m, 48 H, -CH₂-Tt), 3.4-3.5 (m, 96 H, -CH₂-Tt), 4.1-4.3 (m, 8 H, αH lysine, alanine, cysteine), 4.7 (m, 18 H, αH histidine) 7.3 (18 H, imidazole H histidine), 8.6 (18 H, imidazole H histidine).

Oligomer Id: 579  
δ (ppm) = 1.3-1.8 (m, 75 H, γδε H lysine, -CH₃ alanine), 2.2-2.3 (t, 48 H, -CO-CH₂-CH₂-CO-), 1.8-1.9 (m, 24 H, -CO-CH₂-CH₂-CH₂-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH₂-Tt), 3.4-3.5 (m, 96 H, -CH₂-Tt), 4.1-4.3 (m, 26 H, αH amino acids).

Oligomer Id: 578  
Sequence: A-K-(H-K-((H-Gtt)_3-H-A)_2)_2  
δ (ppm) = 1.3-1.8 (m, 33 H, γδε H lysine, -CH₃ alanine), 2.2-2.3 (t, 48 H, -CO-CH₂-CH₂-CO-), 1.8-1.9 (m, 24 H, -CO-CH₂-CH₂-CH₂-CO-), 3.1-3.2 (m, 42 H, βH lysine, histidine), 3.2-3.3 (m, 48 H, -CH₂-Tt), 3.4-3.5 (m, 96 H, -CH₂-Tt), 4.1-4.3 (m,
8 H, αH lysine, alanine), 4.7 (m, 18 H, αH histidine) 7.3 (18 H, imidazole H histidine), 8.6 (18 H, imidazole H histidine).

Oligomer Id: 580

δ (ppm) = 1.3-1.8 (m, 87 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 (m, 26 H, αH amino acids).

Oligomer Id: 582

δ (ppm) = 1.3-1.8 (m, 165 H, γδεH lysine, -CH3 alanine), 2.9-3.0 (m, 54 H, βH lysine), 3.0-3.3 (m, 64 H, βH histidine), 3.9-4.3 (m, 28 H, αH lysine, alanine), 4.7 (m, 32 H, αH histidine) 7.3 (32 H, imidazole H histidine), 8.6 (32 H, imidazole H histidine).

Oligomer Id: 584

δ (ppm) = 1.3-1.8 (m, 213 H, γδεH lysine, -CH3 alanine), 2.9-3.0 (m, 70 H, βH lysine), 3.0-3.3 (m, 96 H, βH histidine), 3.9-4.3 (m, 36 H, αH lysine, alanine), 4.7 (m, 48 H, αH histidine) 7.3 (48 H, imidazole H histidine), 8.6 (48 H, imidazole H histidine).

7.2.2 Linear cysteine-containing Stp oligomers

Sequence: C-Stp

δ (ppm) = 2.5-2.6 (m, 4 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 4 H, -CH2- Tp), 3.48-3.54 (m, 12 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine).

Sequence: C-Stp2

δ (ppm) = 2.5-2.6 (m, 8 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 8H, -CH2- Tp), 3.48-3.54 (m, 24 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine).

Sequence: C-Stp3

δ (ppm) = 2.5-2.6 (m, 12 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 12 H, -CH2- Tp), 3.48-3.54 (m, 36 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine).

Sequence: C-Stp4

δ (ppm) = 2.5-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 16 H, -CH2- Tp), 3.48-3.54 (m, 48 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine).
Sequence: C-Stp₅
δ (ppm) = 2.5-2.6 (m, 20 H, -CO-CH₂-CH₂-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 20 H, -CH₂- Tp), 3.48-3.54 (m, 60 H, -CH₂- Tp), 4.1-4.3 (m, 1 H, αH cysteine).

7.2.3 PPI conjugates

Conjugate Id: 418
Sequence: PPI-(C-C-Stp)₈
δ (ppm) = 1.7-2.0 (m, 28 H, -CH₂-CH₂-CH₂- PPI), 2.5-2.6 (m, 32 H, -CO-CH₂-CH₂-CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 32 H, -CH₂- Tp; m, 148 H, -CH₂- Tp, -CH₂-CH₂-CH₂- PPI), 4.0-4.5 (m, 16 H, αH amino acids).

Conjugate Id: 427
Sequence: PPI-(C-C-Stp)₂₈
δ (ppm) = 1.7-2.0 (m, 28 H, -CH₂-CH₂-CH₂- PPI), 2.5-2.6 (m, 64 H, -CO-CH₂-CH₂-CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 64 H, -CH₂- Tp; m, 244 H, -CH₂- Tp, -CH₂-CH₂-CH₂- PPI), 4.0-4.5 (m, 16 H, αH amino acids).

Conjugate Id: 428
Sequence: PPI-(C-C-Stp)₃₈
δ (ppm) = 1.7-2.0 (m, 28 H, -CH₂-CH₂-CH₂- PPI), 2.5-2.6 (m, 96 H, -CO-CH₂-CH₂-CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 96 H, -CH₂- Tp; m, 340 H, -CH₂- Tp, -CH₂-CH₂-CH₂- PPI), 4.0-4.5 (m, 16 H, αH amino acids).

Conjugate Id: 526
Sequence: PPI-(C-C-Stp)₅₈
δ (ppm) = 1.7-2.0 (m, 28 H, -CH₂-CH₂-CH₂- PPI), 2.5-2.6 (m, 160 H, -CO-CH₂-CH₂-CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 160 H, -CH₂- Tp; m, 532 H, -CH₂- Tp, -CH₂-CH₂-CH₂- PPI), 4.0-4.5 (m, 16 H, αH amino acids).
7.3 Additional analytical Ion Exchange Chromatography traces of four-arm unmodified Stp oligomers

Analytical runs were performed after dialysis in 10 mM HCl on an Äkta Basic HPLC system, column: Resource S 1 ml (GE Healthcare). Buffer A: 10 mM HCl. Buffer B: 10 mM HCl + 3 M NaCl. Flow rate 2 ml/min. Gradient: 2% B to 100% B in 15 min. UV detection at 214 nm and 280 nm.
7.4 AFM images

AFM images of pDNA polyplexes formed at N/P 12 with (A) Stp-based oligomer 402 and (B) Sph-based oligomer 519. (C) Particles formed with Gtt-based oligomer 494 did not form particles detectable by AFM.

pDNA polyplexes were prepared in 20 mM HEPES, pH 7.4 at N/P 12. After 30 min incubation, samples were diluted 1:10 in 20 mM HEPES buffer pH 7.4 and 10µl of the dilution was pipetted onto a freshly cleaved mica surface. Samples were imaged in the tapping mode on a Multimode VIII AFM (Bruker AXS, Santa Barbara, USA). Experiments were performed together with Max Scheible, Department of Physics at ZNN/WSI, Biomolecular Systems and Bionanotechnology, TU Munich, Germany.
7.5 Additional particle size and zeta potential measurements

7.5.1 Five-arm oligomers after complexation with pDNA at N/P 12.

<table>
<thead>
<tr>
<th>Oligomer ID</th>
<th>Sequence</th>
<th>Mean Size [nm]</th>
<th>Mean Pdl</th>
<th>Mean Zeta Potential [mV]</th>
</tr>
</thead>
<tbody>
<tr>
<td>414</td>
<td>A-Stp2-K-(Stp2-C)2</td>
<td>539 ± 80</td>
<td>0.410 ± 0.01</td>
<td>15.3 ± 0.5</td>
</tr>
<tr>
<td>424</td>
<td>A-Stp2-K-(Stp2-C)2</td>
<td>298 ± 47</td>
<td>0.282 ± 0.00</td>
<td>25.0 ± 0.0</td>
</tr>
<tr>
<td>425</td>
<td>A-Stp2-K-(Stp2-C)2</td>
<td>101 ± 37</td>
<td>0.143 ± 0.03</td>
<td>25.0 ± 0.0</td>
</tr>
</tbody>
</table>

7.5.2 Size and zeta potential of siRNA Polyplexes.

Complexation of siRNA with four-arm oligomers at N/P 12.

<table>
<thead>
<tr>
<th>Oligomer ID</th>
<th>Sequence</th>
<th>Mean Size [nm]</th>
<th>Mean Pdl</th>
<th>Mean Zeta Potential [mV]</th>
</tr>
</thead>
<tbody>
<tr>
<td>392</td>
<td>A-K-(Stp2-C)2</td>
<td>409 ± 79</td>
<td>0.267 ± 0.01</td>
<td>32.6 ± 0.4</td>
</tr>
<tr>
<td>402</td>
<td>A-K-(Stp4-C)2</td>
<td>356 ± 82</td>
<td>0.273 ± 0.01</td>
<td>34.7 ± 0.3</td>
</tr>
</tbody>
</table>

Complexation of siRNA with five-arm oligomers at N/P 12.

<table>
<thead>
<tr>
<th>Oligomer ID</th>
<th>Sequence</th>
<th>Mean Size [nm]</th>
<th>Mean Pdl</th>
<th>Mean Zeta Potential [mV]</th>
</tr>
</thead>
<tbody>
<tr>
<td>414</td>
<td>A-Stp2-K-(Stp2-C)2</td>
<td>489 ± 44</td>
<td>0.338 ± 0.01</td>
<td>28.0 ± 0.5</td>
</tr>
<tr>
<td>424</td>
<td>A-Stp2-K-(Stp2-C)2</td>
<td>375 ± 62</td>
<td>0.210 ± 0.02</td>
<td>30.5 ± 0.8</td>
</tr>
<tr>
<td>425</td>
<td>A-Stp2-K-(Stp2-C)2</td>
<td>n.d.</td>
<td>-</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

n.d. not detectable
### 7.6 Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BCNP</td>
<td>Boc-Cys(NPys)-OH</td>
</tr>
<tr>
<td>Boc</td>
<td>tert-Butyloxycarbonyl</td>
</tr>
<tr>
<td>CMPI</td>
<td>2-Chloro-1-methylpyridinium iodide</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>Da</td>
<td>Dalton</td>
</tr>
<tr>
<td>DCM</td>
<td>Dichloromethane</td>
</tr>
<tr>
<td>DCU</td>
<td>Dicyclohexylurea</td>
</tr>
<tr>
<td>DIPEA</td>
<td>Diisopropylethylamine</td>
</tr>
<tr>
<td>DLS</td>
<td>Dynamic light scattering</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle’s Medium</td>
</tr>
<tr>
<td>DMF</td>
<td>Dimethylformamide</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNTB</td>
<td>5,5’-dithiobis-2-nitrobenzoic acid (Ellman’s reagent)</td>
</tr>
<tr>
<td>DTT</td>
<td>Dithiothreitol</td>
</tr>
<tr>
<td>eGFP</td>
<td>Enhanced green fluorescent protein</td>
</tr>
<tr>
<td>EPR</td>
<td>Enhanced permeability and retention</td>
</tr>
<tr>
<td>EtBr</td>
<td>Ethidium bromide</td>
</tr>
<tr>
<td>FBS</td>
<td>Foetal bovine serum</td>
</tr>
<tr>
<td>Fmoc</td>
<td>9-Fluorenylmethyloxycarbonyl</td>
</tr>
<tr>
<td>GSH</td>
<td>Glutathione</td>
</tr>
<tr>
<td>Gtt</td>
<td>Glutaroyl-triethylentetraamine</td>
</tr>
<tr>
<td>HBG</td>
<td>HEPES-buffered glucose</td>
</tr>
<tr>
<td>HEPES</td>
<td>N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid)</td>
</tr>
<tr>
<td>HOBt</td>
<td>1-Hydroxybenzotriazol</td>
</tr>
<tr>
<td>IEX</td>
<td>Ion exchange</td>
</tr>
<tr>
<td>LL</td>
<td>Low load</td>
</tr>
<tr>
<td>linPEI</td>
<td>Linear polyethylenimine</td>
</tr>
<tr>
<td>Luc</td>
<td>Luciferase</td>
</tr>
<tr>
<td>MALDI</td>
<td>Matrix assisted laser desorption ionization mass spectrometry</td>
</tr>
<tr>
<td>MES</td>
<td>2-(N-morpholino)ethanesulfonic acid</td>
</tr>
<tr>
<td>MTT</td>
<td>Methylthiazoletetrazolium</td>
</tr>
<tr>
<td>Mw</td>
<td>Molecular weight</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>MWCO</td>
<td>Molecular weight cut-off</td>
</tr>
<tr>
<td>¹H-NMR</td>
<td>Proton nuclear magnetic resonance</td>
</tr>
<tr>
<td>NPys</td>
<td>3-Nitro-2-pyridinesulfenyl</td>
</tr>
<tr>
<td>N/P-ratio</td>
<td>Molar ratio of protonable nitrogens to phosphates</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>pDNA</td>
<td>Plasmid deoxyribonucleic acid</td>
</tr>
<tr>
<td>pEGFPLuc</td>
<td>Plasmid encoding for luciferase under control of the EGFP promoter/enhancer</td>
</tr>
<tr>
<td>PEI</td>
<td>Polyethylenimine</td>
</tr>
<tr>
<td>Pfp</td>
<td>Pentafluorophenol</td>
</tr>
<tr>
<td>Pip</td>
<td>Piperidine</td>
</tr>
<tr>
<td>PPI</td>
<td>Polypropylenimine</td>
</tr>
<tr>
<td>PyBOP®</td>
<td>Benzotriazol-1-yl-oxytrypyrrolidinophosphonium-hexafluorophosphate</td>
</tr>
<tr>
<td>RBF</td>
<td>Round-bottom flask</td>
</tr>
<tr>
<td>RISC</td>
<td>RNA-induced silencing complex</td>
</tr>
<tr>
<td>RLU</td>
<td>Relative light units</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RNAi</td>
<td>RNA interference</td>
</tr>
<tr>
<td>RP-HPLC</td>
<td>Reversed-Phase High-performance liquid chromatography</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>SAR</td>
<td>Structure-activity relationship</td>
</tr>
<tr>
<td>SEC</td>
<td>Size exclusion chromatography</td>
</tr>
<tr>
<td>siRNA</td>
<td>Small interfering RNA</td>
</tr>
<tr>
<td>Sph</td>
<td>Succinyl-pentaethylenhexamine</td>
</tr>
<tr>
<td>SPS</td>
<td>Solid-phase synthesis</td>
</tr>
<tr>
<td>Stp</td>
<td>Succinoyl-tetraethylenpentamine</td>
</tr>
<tr>
<td>Succ</td>
<td>Succinoyl</td>
</tr>
<tr>
<td>TCEP</td>
<td>Tris(2-carboxyethyl) phosphine</td>
</tr>
<tr>
<td>TFA</td>
<td>Trifluoroacetic acid</td>
</tr>
<tr>
<td>TIS</td>
<td>Triisopropylsilane</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin layer chromatography</td>
</tr>
<tr>
<td>Trt</td>
<td>Trityl</td>
</tr>
<tr>
<td>UV-VIS</td>
<td>Ultraviolet-Visible spectroscopy</td>
</tr>
<tr>
<td>w/w</td>
<td>Weight to weight ratio (e.g. of conjugate to nucleic acid)</td>
</tr>
</tbody>
</table>
7.7 Publications

7.7.1 Original papers

Schaffert, David; Troiber, Christina; Salcher, Eveline E.; Fröhlich, Thomas; Martin, Irene; Badgujar, Naresh; Dohmen, Christian; Edinger, Daniel; Kläger, Raphaela; Maiwald, Gelja; Farkasova, Katarina; Seeber, Silke; Jahn-Hofmann, Kerstin; Hadwiger, Philipp; Wagner, Ernst: Solid-phase synthesized sequence-defined t-shape, i-shape and u-shape polymers for pDNA and siRNA delivery, Angewandte Chemie International Edition (2011), 50, 8986-8989

Fröhlich, Thomas; Edinger, Daniel; Kläger, Raphaela; Troiber, Christina; Salcher, Edith; Badgujar, Naresh; Martin, Irene; Schaffert, David; Cengizeroglu, Arzu; Hadwiger, Philipp; Vornlocher, Hans-Peter; Wagner, Ernst: Structure-activity relationships of siRNA carriers based on sequence-defined oligo (ethane amino) amides, Journal of Controlled Release (2012), 160, 532-541

Salcher, Eveline E.; Kos, Petra; Fröhlich, Thomas; Badgujar, Naresh; Scheible, Max; Wagner, Ernst: Sequence-defined Four-arm Oligo(ethanamino)amides for pDNA and siRNA Delivery: Impact of Building Blocks on Efficacy, Journal of Controlled Release (2012), 164, 380-386

Lächelt, Ulrich; Kos, Petra; Mickler, Frauke M.; Salcher, Eveline E.; Rödl, Wolfgang; Badgujar, Naresh; Bräuchle, Christoph; Wagner, Ernst (2013) Fine-tuning of proton sponges by precise diaminooethanes and histidines in pDNA polyplexes. Submitted.

Kos, Petra; Scholz, Claudia; Salcher, Eveline E.; Herrmann, Annika; Wagner, Ernst: Gene transfer with sequence-defined oligo(ethanamino)amides bioreducibly attached to a propylenimine dendrimer core. Submitted.

7.7.2 Book chapters

E. Salcher and E. Wagner: Chemically programmed polymers for targeted DNA and siRNA transfection, Topics in Current Chemistry (2010); 296:227-249

E. Salcher and E. Wagner: Nanoencapsulation of oligonucleotides for therapeutic use, Nucleic Acids Nanotechnology, Manuscript submitted
7.7.3 Poster presentation

E. Salcher, D. Schaffert, Thomas Fröhlich, P. Kos, E. Wagner: Solid-Phase Supported Synthesis of Branched Cationic Polymers for Gene Delivery, CeNS Workshop, Venice, Italy, September 2011

7.7.4 Oral presentation

E. Salcher, D. Schaffert, Thomas Fröhlich, P. Kos, E. Wagner: Solid-phase Synthesis of Precise Branched Polymers for Gene Delivery, Doktorandenseminar Fakultät für Chemie und Pharmazie, LMU München, Munich, April 2011
8 REFERENCES


The completion of this thesis would not have been possible without the support of various people I would like to acknowledge in the following lines.
First of all, I would like to thank my supervisor Prof. Ernst Wagner for giving me the opportunity to be a part of his group. His scientific support, the creative freedom he offered and his great patience motivated my work all through the years.
A huge thank you goes to Dr. David Schaffert for introducing me to the daily lab work and the willingness to share his profound knowledge not only of SPS.
A great thank you goes to my colleagues of the “polymer group”: Christina, Christian D., Naresh, Uli, Claudia, Petra and Thomas for the good teamwork, helpful discussions and for being great colleagues I could always rely on. Additionally, thank you to Petra and Thomas for performing uncountable transfection experiments.
Thank-you to my (former) lab buddies Terese, Claudia (mmmmhh), Christian D., Kevin and Wolfgang for sharing joy and frustration all through the years. Thank-you to my “downstairs buddies” Christian M., Uli and Arzu for funny and fruitful conversations and also to the other members of the Wagner lab I did not mention by name for contributing to a pleasant working atmosphere.
I would also like to thank to Dr. Martina Rüffer for patiently introducing me (again) to the secrets of cellular plant drawing and Bavarian fauna. Her deep knowledge on plants and enthusiasm of sharing it made me look forward to the summer terms. I thank her also for sharing her passion for contemporary literature by providing me with interesting new books.
I am also very grateful to Wolfgang Rödl, who heard the most silent cries of desperation whenever some device was not working and was immediately there to help.
I would also like to thank the people from our former cooperation partner Axolabs GmbH (formerly: Roche Kulmbach GmbH) for the great collaboration and support. Thank you also Dr. Lars Allmendinger and his team for measuring uncountable NMRs. Also, thank-you to Max Scheible from the Simmel lab for performing the AFM measurements.
My gratitude goes also, more than words can say, to my parents and my husband Christian. For always catching me when I was about to fall and making dark days
sunny. For always showing me the way back when I was about to get lost. For laughing with me. For drying my tears. For being in my life. Thank you.